

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised trial of palate surgery at 6 months versus 12 months of age

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029780
Article Type:	Protocol
Date Submitted by the Author:	15-Feb-2019
Complete List of Authors:	<p>Shaw, William; University of Manchester, School of Medical Sciences  Semb, Gunvor; University of Manchester Faculty of Biology, Medicine and Health, Division of Dentistry  Lohmander, Anette; Division of Speech &amp; Language Pathology, Karolinska Institute, Functional Area Speech &amp; Language Pathology,  Persson, Christina; Goteborgs universitet Institutionen for neurovetenskap och fysiologi, Department of Rehabilitation and Health, Sahlgrenska academy  Willadsen, Elisabeth; University of Copenhagen, Department of Nordic Studies and Linguistics  Clayton-Smith, Jill; University of Manchester Faculty of Biology, Medicine and Health, Division of Evolution &amp; Genomic Sciences  Trindade, Inge; 5Facu Faculdade de Odontologia de Bauru,, Hospital de Reabilitação de Anomalias Craniofaciais Universidade de São Paulo,  Munro, Kevin; The University of Manchester, Manchester Centre for Audiology and Deafness, School of Health Sciences,  Gamble, Carrol; University of Liverpool, Clinical Trials Research Centre  Harman, Nicola; University of Liverpool, Clinical Trials Research Centre  Conroy, Elizabeth; University of Liverpool, Clinical Trials Research Centre  Weichart, Dieter; University of Manchester Faculty of Biology, Medicine and Health  Williamson, Paula ; University of Liverpool, Clinical Trials Research Centre</p>
Keywords:	unilateral cleft palate, randomised clinical trial, palatal surgery, velopharyngeal function, syllable inventory, Sommerlad technique

SCHOLARONE™  
Manuscripts

# 1 **Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised** 2 **trial of palate surgery at 6 months versus 12 months of age**

3 **Authors:** William Shaw<sup>1a</sup>, Gunvor Semb<sup>1a</sup>, Anette Lohmander<sup>2</sup>, Christina Persson<sup>3</sup>, Elisabeth  
4 Willadsen<sup>4</sup>, Jill Clayton-Smith<sup>1c</sup>, Inge Kiemle Trindade<sup>5</sup>, Kevin J Munro<sup>1b</sup>, Carrol Gamble<sup>6</sup>, Nicola  
5 L Harman<sup>6</sup>, Elizabeth J Conroy<sup>6</sup>, Dieter Weichart<sup>1a</sup>, and Paula Williamson<sup>6</sup>

6 Correspondence to Professor William Shaw, The University of Manchester, Division of Dentistry,  
7 Coupland 3 Building, Manchester M13 9PL email: [bill.shaw@manchester.ac.uk](mailto:bill.shaw@manchester.ac.uk)

## 9 **ABSTRACT**

10 **Introduction:** Cleft palate is amongst the most common birth abnormalities. The success of primary  
11 surgery in the early months of life is crucial for successful feeding, speech, hearing, dental  
12 development and facial growth. Over recent decades, age at palatal surgery in infancy has reduced.  
13 This has led to palatal closure in one-stage procedures being carried out around the age of 12 months,  
14 but in some cases as early as 6 months. The primary objective of the TOPS trial is to determine  
15 whether surgery for cleft palate performed at 6 or 12 months of age is most beneficial for speech  
16 outcomes.

17 **Methods and analysis:** Infants with a diagnosis of non-syndromic isolated cleft palate will be  
18 randomised to receive standardised primary surgery (Sommerlad technique) for closure of the cleft  
19 at either 6 months or 12 months, corrected for gestational age. The primary outcome will be perceived  
20 insufficient velopharyngeal function at 5 years of age. Secondary outcomes measured across 12  
21 months, 3 and 5 years will include growth, safety of the procedure, dentofacial development, speech,  
22 hearing level and middle ear function. Video and audio recordings of speech will be collected in a  
23 standardised age-appropriate manner and analysed independently by multiple speech and language  
24 therapists (SLTs). The trial aims to recruit and follow up 300 participants per arm. Data will be  
25 analysed according to the intention to treat principle using a 5% significance level. All analyses will  
26 be pre-specified within a full and detailed statistical analysis plan.

27 **Ethics and dissemination:** Ethical approval has been sought in each participating country according  
28 to country specific procedures. Trial results will be presented at conferences, published in peer-  
29 reviewed journals and disseminated through relevant patient support groups.

30 **Protocol version 5.0 22<sup>nd</sup> August 2018**

31 **Registration details:** ClinicalTrials.gov Identifier NCT00993551.

32 **Funding:** US National Institutes of Health (funder reference: 5U01DE018664/1U01DE018837)

33  
34 **Keywords:** unilateral cleft palate, randomised clinical trial, TOPS, palatal surgery,  
35 velopharyngeal function, syllable inventory, Sommerlad technique

## Strengths and limitations of the study

- International trial covering speech development in children across Scandinavia, the UK, and Brazil
- Surgical repair was calibrated across surgeons who were all trained in the Sommerlad technique.
- Longitudinal speech assessments at 12 months, 3 and 5 years will be independently analysed by multiple speech and language therapists whose ratings will be calibrated on practice recordings.
- Standardised assessments of additional outcomes include postoperative complications, hearing levels, middle ear function and dentofacial development.
- The study excludes co-existing conditions such as syndromic cleft palate or severe developmental delays that are known to adversely affect speech development or its assessment

## INTRODUCTION

Clefts of the lip and/or palate, occurring with an incidence of about 1 per 600 births, are among the most common birth anomalies. This trial will focus on isolated clefts of the palate, which occur with a global incidence of 4.5 per 10,000 births (1). Depending on geographic location, the prevalence of isolated clefts of the palate ranges from 1.8 to 14.6 per 10,000 (1).

The timing of palatal surgery has been a controversial issue since the 1930s (2). Traditionally, rationale for delaying hard palate surgery was partly based on the belief that postponing the trauma of palatal closure may reduce maxillary growth disturbance. However, there is little evidence that facial skeletal growth in individuals with isolated cleft palate is substantially affected by different surgical protocols, though maxillary arch form, especially transversely, may be affected (3-6).

Over recent decades, the age at which palatal surgery is carried out has reduced. This has led to one-stage palatal closure within 12 months of age at cleft units in Europe and the USA. Protagonists of early closure of the palatal cleft have proposed that since speech is a learned behaviour, the sooner an intact anatomy is created, the better (7-10). As yet however, there is no evidence that early surgery would lead to better speech development.

### Rationale

The widespread uncertainty surrounding the timing of palatal closure was reflected in the diversity of protocols currently employed by the Scandcleft Research Group, a partnership of Scandinavian and UK cleft lip and palate centres (11-22). The Scandcleft Research Group, identified this uncertainty as a priority research question for a future trial. Its aim was to determine whether, in infants with cleft palate, repair at either age 6 or at 12 months (corrected for gestational age) would achieve better speech outcomes. The design of the trial was supported by a planning grant from the National Institute of Dental and Craniofacial Research (NIDCR), a substream of the US National Institute of Health, who subsequently funded the proposed trial.

### Objectives

The aim of this project is to determine whether, in infants with isolated cleft palate, it is better to perform primary surgery at age 6 or 12 months (corrected for gestational age). Gestational age will be assessed based upon the date of the last menstrual period and the infant's date of birth (full term

78 defined as day 1 of the 40<sup>th</sup> week of pregnancy), thus taking account of prematurity. This research  
 79 will investigate the effect of the timing of surgery by assessing and comparing speech development  
 80 outcomes measured across 12 months, 3 years and 5 years. In addition, secondary outcomes include  
 81 growth, perioperative complications, dentofacial development, hearing level and middle ear function.

## 82 METHODS AND ANALYSIS

### 83 *Design*

84 Timing Of Primary Surgery for cleft palate (TOPS) is an international, multi-site trial using a parallel  
 85 arm design aiming to detect whether surgery at 6 months is superior to surgery at 12 months. Infants  
 86 will be randomised to receive primary surgery for cleft palate using a standardised technique (the  
 87 Sommerlad technique (23)) at either age 6 or age 12 months (corrected for gestational age). The study  
 88 design of TOPS trial is illustrated in Figure 1.

### 89 *Setting*

90 The trial will be conducted by the cleft palate teams based in centres across the UK, Scandinavia and  
 91 Brazil. Criteria for selection of sites is based primarily on ability to enrol a high volume of patients  
 92 into the trial. A list of the TOPS trial sites is provided in Table 1. The cleft team at each centre  
 93 generally includes cleft surgeon(s), nursing staff, cleft speech and language therapist(s), clinical  
 94 geneticist(s)/paediatrician(s), audiologist(s), orthodontist(s) and psychologist(s)/social worker(s)

95 **Table 1: TOPS trial clinical sites**

Country	Sites
<b>Brazil</b>	University of São Paulo (HRAC Bauru)
<b>Denmark</b>	Copenhagen Cleft Palate Centre / Århus Speech and Hearing Institute
<b>Norway</b>	Oslo University Hospital
	Helse Bergen HF
<b>Sweden</b>	Malmö University Hospital
	Göteborg University
	Karolinska University Hospital (Stockholm)
	University of Linköping
	Umeå University
<b>United Kingdom</b>	Uppsala University
	Royal Manchester Children's Hospital
	Alder Hey Children's NHS Foundation Trust
	Royal Belfast Hospital for Sick Children
	Birmingham Children's Hospital
	Royal Victoria Infirmary, Newcastle
	University Hospitals Bristol NHS Foundation Trust
	Morrison Hospital, Abertawe Bro Morgannwg University Hospital Board, Swansea
	Leeds General Infirmary
	Royal Hospital for Sick Children, Glasgow
	Royal Hospital for Sick Children, Edinburgh
	Salisbury NHS Foundation Trust
The Children's Hospital, John Radcliffe Hospital, Oxford	

## 96 ***Eligibility criteria***

97 All infants referred to the participating specialised cleft lip and palate centres are eligible to enter the  
98 trial if they meet the following inclusion and none of the exclusion criteria:

- 99 a. isolated cleft palate;
- 100 b. medically fit for surgery at 6 months, corrected for gestational age;
- 101 c. Written informed proxy consent;
- 102 d. One parent/carer must be a native language speaker of the majority language in the country  
103 of residence.

104 Infants with any of the following will be excluded from the study:

- 105 a. Consent not obtained;
- 106 b. Infants with severe developmental delay (as measured on DENVER II) or syndromic cleft  
107 palate (except Van der Woude syndrome, which can be included if hearing is not affected)  
108 will be excluded;
- 109 c. Congenital sensorineural hearing loss or structural middle ear anomalies;
- 110 d. Sommerlad technique could not be performed due to variation in the anatomical presentation;
- 111 e. Infants presenting with submucous cleft palate (defined by the classical triad of signs, bifid  
112 uvula, bony defect of the hard palate, muscular diastasis, as described by Jensen et al. (24))
- 113 f. Where the language spoken at home by at least one parent is not the majority language in the  
114 country of residence.

115 Since not all syndromic disorders will present prior to recruitment, all participants will undergo  
116 genetic testing to exclude chromosome abnormalities at the time of surgery. If a chromosome  
117 abnormality or another genetic syndrome is identified later in the study the data for these participants  
118 will be analysed separately. The same will apply if the participant fails the DENVER II  
119 developmental test at 3 year follow up.

## 120 ***Consent***

121 Informed consent will be sought from the infant's parent/guardian by a member of the local trial  
122 team, and families who decline to participate will receive surgery in line with the hospital's current  
123 practice together with the same level of care and support as families participating in the trial. Consent  
124 forms used in the TOPS trial in the UK are shown in Supplementary Materials Nos. 1, 2 and 3; these  
125 forms were adapted and translated for use in the other participating countries while maintaining key  
126 content. The final consent forms in Brazilian-Portuguese, Danish, Norwegian and Swedish were  
127 translated to English to check for accuracy and completeness. Participants can withdraw from the  
128 trial at any time without giving an explanation, and their child's care will not be affected.

129 To reduce potential burden to families, where possible, trial information will be collected at visits  
130 scheduled in line with routine visits made to the site as part of the infant's ongoing care.

## 131 ***Randomisation***

132 Infants meeting the eligibility criteria will be randomised to 6 or 12 month surgery, corrected for  
133 gestational age, in a ratio 1:1 using a minimisation routine incorporating a random element to reduce  
134 predictability. Allocations will be delivered via a password protected web-based system.

1  
2  
3 135 Every effort will be made to arrange surgery within one of week of the target date. However, surgery  
4 136 may take place up to two weeks before or four weeks after the target date. The estimated timing of  
5 137 surgery and the allowed time window for the surgery will be calculated by the online randomisation  
6 138 system and provided to the trial site at the time of randomisation.  
7  
8

9 139 ***Interventions***

10  
11 140 The Sommerlad surgical technique (23)] will be used in all participants at 6 months or 12 months  
12 141 corrected for gestational as determined by randomisation. This technique will be standardised across  
13 142 all surgeons, including those who already use the technique, by receiving direct instruction from Mr  
14 143 Brian Sommerlad in the operating theatre. Written descriptions and a video of the surgical procedure  
15 144 will also be provided.  
16  
17

18 145 ***Blinding***

19  
20 146 The nature of the interventions prevents this trial from being blind to participants or their carers.  
21 147 However, speech and audiometry outcome assessments, at age 3 and 5 years, will be conducted and  
22 148 rated blind to the randomly allocated group.  
23  
24

25 149 ***Outcome Measures***

26  
27 150 The primary endpoint for the TOPS trial is defined as a dichotomous outcome of whether the child  
28 151 has been perceived by the SLTs to have insufficient velopharyngeal function at age 5 years or not.  
29 152 This is measured by velopharyngeal (VPC) sum, which is an overall score on the scale 1-6 (25).  
30 153 Scores  $\geq 4$  on this scale will be considered insufficient.  
31  
32

33 154 The secondary endpoints are summarised in Box 1 and Table 2 (Schedule of Assessments).  
34  
35  
36 155  
37  
38 156  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

157 Box 1: Secondary Endpoints

1. Velopharyngeal function at age 5 years;
  - a. Velopharyngeal composite score summary (VPC sum)
  - b. Insufficient velopharyngeal function (VPC rate)
2. Velopharyngeal function at age 3 years;
  - a. Insufficient velopharyngeal function (VPC rate)
  - b. Velopharyngeal insufficiency symptoms
3. Canonical babbling at age 12 months:
  - a. Canonical babbling present
  - b. Canonical babbling ratio
  - c. Consonant inventory
4. Articulation at age 3 years:
  - a. Percent consonants correct (PCC)
  - b. Percent correct placement (PCP)
  - c. Percent correct manner (PCM)
  - d. Non-oral consonant errors
  - e. Oral consonant errors
5. Articulation at age 5 years:
  - a. Percent consonants correct (PCC)
  - b. Percent correct placement (PCP)
  - c. Percent correct manner (PCM)
  - d. Non-oral consonant errors
  - e. Oral consonant errors
6. Postoperative/long term complications:
  - a. Dehiscence
  - b. Infection
  - c. Evidence of fistula
7. Hearing level:
  - a. *At 12 months*
    - i. Abnormal Transient Otoacoustic Emission (TEOAE)
    - ii. Abnormal Soundfield audiometry
  - b. *At 3 and 5 years*
    - i. Abnormal Puretone audiometry in at least one ear
    - ii. Abnormal Puretone audiometry in both ears
    - iii. Severity of better ear (normal, mild, moderate, severe, profound)
8. Middle ear function
  - a. Flat line Tympanogram in at least one ear (12 months, 3 years, 5 years)
  - b. Flat line Tympanogram in both ears (12 months, 3 years, 5 years)
9. Dentofacial development at age 5 years:
  - a. Soft tissue ANB (the angle between soft tissue nasion, A point, and B point on a profile photograph)
  - b. Maxillary arch constriction score (using modified Huddart/Bodenham scoring system)
10. Growth at 12 months:
  - a. Nude weight
  - b. Crown to heel length
  - c. Occipitofrontal circumference

158

159 **Speech outcome assessments**

160 To ensure quality of speech data, all sites will receive identical high quality recording equipment  
 161 (video recorder JVC-GY-HM100 series, audio recorder H4n/H5 Handy recorder, and microphone  
 162 Rode NT4/NT5) to be used at each follow-up recording according to a detailed standard operating



163 procedure. Before data collection starts at each follow up age, all SLTs will participate in a three-day  
 164 calibration meeting. Afterwards, a series of video-audio practice recordings will be completed and  
 165 quality checked. When sufficient recording quality has been reached, the site receives approval that  
 166 they can start the trial recordings. To train the SLTs who are going to perform blinded speech  
 167 assessments, a specific procedure has been developed. This includes theoretical lectures on  
 168 development of speech and language in children with cleft palate and methodological considerations  
 169 on assessment/rating, and listener training with discussions and personal feedback. Before the  
 170 assessments start, all SLTs need to pass a test with a specified level of intra- and inter-rater reliability.  
 171 They also have to pass a hearing test.

172 At 12-months of age, assessments will be done cross-linguistically. At age 3 and 5, SLT rating will  
 173 be confined to records of children sharing the SLT's native language.

174 Vocalisations of 12-month old children will be assessed with adjusted real time listening, as described  
 175 by Ramsdell et al (26). The SLTs will listen to a 45 minutes video recording, of a play session between  
 176 the child and carer, divided in two parts (22 minutes each). The SLT will register every syllable a  
 177 child produces as canonical or not, in real time, using a software, TimeStamper, specifically  
 178 developed for this study (27). At the end of each recording, the SLT indicates if the child babbled  
 179 canonically or not, and lists the syllables the child produced with control. In this way, the variables  
 180 canonical babbling present, canonical babbling ratio, and consonant inventory are obtained.

181 The methodology for the 5-year assessment of articulation and velopharyngeal function cross-  
 182 linguistically was developed within the Scandleft study (12, 18, 22) and will be extended to include  
 183 Brazilian Portuguese. At the 5-year assessment, 36 target consonants from the TOPS single word test  
 184 will be transcribed phonetically for assessment of articulation and VPI-symptoms. Target words  
 185 include similar target sounds in the same position and with similar phonetic context across languages.  
 186 Further, repetition of sentences and continuous speech are collected, as well as nasalance scores  
 187 (Nasometer™), and parent-reported intelligibility estimates of how well their children's speech is  
 188 understood by different listeners (Intelligibility in context scale (28)). The 3-year assessment will be  
 189 based on 30 of the 36 words used in the 5-year assessment, and target consonants will be transcribed  
 190 phonetically for assessment of articulation. Error types will be classified automatically by a  
 191 predefined script that will also allow calculation of PCC, PCP, and PCM. The VPC-rate will be rated  
 192 by SLTs from continuous speech both at age 3 and 5 years

Outcome Measures	Assessment Schedule (age is corrected for gestational age)					
	Assessments	Post-surgery		12 months	3 years	5 years
		48 hours	30 days			
Surgical Complications	Dehiscence	√	√			
	Infection	√	√			
	Evidence of Fistula		√		√	√

Table 2:

196 Schedule of Assessments

TOPS Trial Protocol paper\_V11.0 05 02 2019.docx

<b>Growth</b>	Nude Weight			√		
	Crown to heel length			√		
	Occipitofrontal Circumference			√		
<b>Canonical Babbling</b>	Canonical Babbling present <sup>e</sup>			√		
	Canonical Babbling ratio <sup>e</sup>			√		
	Consonant Inventory <sup>e</sup>			√		
<b>Velopharyngeal Function</b>	Velopharyngeal composite score summary (VPC-sum)					√ <sup>a,b</sup>
	Insufficient Velopharyngeal function (VPC rate)				√ <sup>c</sup>	√ <sup>d</sup>
	Velopharyngeal insufficiency Symptoms				√ <sup>a</sup>	
<b>Articulation</b>	Percent Consonant Correct (PCC) <sup>a</sup>				√	√
	Percent Correct Placement (PCP) <sup>a</sup>				√	√
	Percent Correct Manner (PCM) <sup>a</sup>				√	√
	Non-oral consonant errors <sup>a</sup>				√	√
	Oral Consonant errors <sup>a</sup>				√	√
<b>Hearing Level</b>	Abnormal Transient Otoacoustic Emission (TEOAE)			√		
	Abnormal Soundfield Audiometry			√		
	Abnormal Pure Tone Audiometry in at least one ear*				√	√
	Abnormal Pure tone Audiometry in both ears*				√	√
	Severity of better ear*				√	√
	Soundfield Audiometry*				√	√
<b>Middle Ear Function</b>	Flat Line Tympanogram in at least one ear			√	√	√
	Flat Line Tympanogram in both ear			√	√	√

<b>Dentofacial Development</b>	Soft Tissue ANB**					√
	Maxillary arch Constriction score***					√
	<b>Others</b>	DENVER II Developmental Assessment****				√
	Intelligibility in Context Scale Questionnaire for parents (ICS)					√
	Local site questionnaire*****				√	√

202

203

204

205

206

207 \*: if puretone audiometry could not be performed then Soundfield audiometry will be performed

208 \*\*: the angle between soft tissue nasion A point and B pint on a profile photograph

209 \*\*\*: maxillary arch constriction score is determined using modified Huddart/Bodenham scoring system

210 \*\*\*\*: DENVER II developmental Assessment is carried out at the time of surgery

211 \*\*\*\*\*: Local site questionnaire sent to local speech and language therapists outside TOPS research team to collect data on direct and indirect therapy given to the child in the intervals between assessment visits

213 Sources of speech assessments; a: TOPS picture naming test, b: nine word string, c: spontaneous speech, d: spontaneous speech (retelling of bus story) and e: video of play interaction.

215

## 216 Patient and Public Involvement

217 Parents of children with cleft palate were approached by their orthodontist / surgeons prior to enrolment. Patients and their parents were not initially involved in the design of the study. However, 218 a representative from the Cleft Lip & Palate Association (the charity for Cleft Lip & Palate in the 219 UK) is a member of the Trial Steering Committee. Therefore, providing ongoing insight from a parent 220 perspective with regards to the execution of this study and the dissemination of results. 221

## 222 Data collection and management

223 Trial data will be recorded on Case Report Forms (CRFs) and identifiable only by randomisation 224 number. The data from completed CRFs will be entered onto the trial specific MACRO database by 225 the Data Manager or appropriately trained personnel at the Data Coordinating Centre.

## 226 ***Video and audio recording***

227 Once recorded, video and audio recordings will be saved onto encrypted USB drives. They will be  
228 posted to the Data Coordinating Centre where, upon receipt, they will be logged and stored onto the  
229 trial specific secure server. This server will be backed up once a day to ensure data is not lost once  
230 received. Recordings are quality checked by the Core Speech Group and/or the Trial Administrative  
231 Centre. A satisfactory recording is one that passes pre-specified quality checks on lighting, length  
232 and sound. Quality checks will be performed regularly and feedback to site will be provided on their  
233 suitability for assessment.

## 234 ***Maxillary arch impressions***

235 Maxillary arch impressions will be obtained at the time of surgery to provide a mould for plaster  
236 casts, which are sent to the TOPS Administrative Centre at the University of Manchester.

237 In addition, impressions of the maxillary and mandibular dental arches will be obtained at the 5 year  
238 follow-up appointment. Impressions are taken by a designated member of staff (usually the  
239 orthodontist) using appropriate impression material. The occlusion will be registered with a wax  
240 wafer in the position of maximal intercuspation. The study models made from the impressions will  
241 be stored at the TOPS Administrative Centre.

## 242 243 ***Photographs***

244 Intra-oral photographs will be taken at the time of surgery, and frontal and lateral photographs will  
245 be obtained at the 5-year visit. The photographs will be saved onto encrypted USBs, upon receipt by  
246 the Data Coordinating Centre they will be logged and stored onto trial specific secure hard drives.

## 247 ***Statistical analysis and sample size considerations***

### 248 ***Proposed sample size***

249 300 patients per arm will allow a reduction in insufficient velopharyngeal function at 5 years from  
250 40% to 29% to be detected with 81% power using a chi-square test (2 sided significance test at 0.05  
251 level). The estimate of 40% was obtained from a pilot trial in 50 five year of patients, collected during  
252 the planning period for this grant application (12). To allow an approximate drop out of 10%, 648  
253 participants will be recruited. However to consider the potential impact of variability around the value  
254 of 40%, 300 patients per group would provide 80% power to detect a reduction from 30% to 20%  
255 and 76% power to detect a reduction from 20% to 12%.

256  
257 The trial enrolment, allocation, follow up and analysis will be reported using the “Consolidated  
258 Standard of Reporting Trials” (“CONSORT”) (29) and the International Conference on  
259 Harmonisation E9 guidelines (30). A full and detailed statistical analysis plan (31) will be developed  
260 prior to the final analysis of the trial. The main features of the statistical analysis plan are included  
261 here.

262 The primary analysis will be by intention-to-treat principle, as far as is practically possible using a  
263 5% significance level throughout. Rather than adjust for multiplicity of secondary outcomes, relevant

264 results from other studies already reported in the literature will be taken into account in the  
265 interpretation. The approach to formal analyses will be dependent on outcome type as follows:

- 266 • *Dichotomous outcome* will be compared between the two groups using a chi-squared test and  
267 the effect estimate will be reported in terms of the relative risk and 95% confidence interval.
- 268 • *Short ordinal outcomes* will be compared using a chi-squared test for trend.
- 269 • *Continuous and long ordinal outcomes* will be compared between the two groups using a two  
270 group t-test. The difference in means will be presented with a 95% confidence interval.

271 Baseline and operative characteristics and safety data will be presented using descriptive statistics  
272 only.

273 If the percentage of major protocol deviations exceeds 10% and the trial management group consider  
274 this analysis appropriate, a per protocol analysis in which pre-specified major protocol deviations  
275 indicate exclusion of a participant from the analysis set will be conducted.

### 276 **Trial oversight and monitoring**

277 The Trial Management Group (TMG), Trial Steering Committee (TSC) and Data Safety and  
278 Monitoring Board (DSMB) will provide ongoing oversight and will monitor accruing trial data. The  
279 roles, responsibilities and composition of each of these committees are provided in Supplementary  
280 Material No. 4. A risk assessment has been conducted and used to inform a trial specific monitoring  
281 plan agreed by the independent oversight committees.

### 282 **Trial status and timeline**

283 The overall programme commenced 13/07/2010. Applications for ethics approval were submitted  
284 10/11/2009. Recruitment to the trial commenced 13/07/2010. Participants will be followed up until  
285 30<sup>th</sup> July 2020.

286 This trial completed recruitment on 21<sup>st</sup> July 2015 and the last patient is due to attend their last visit  
287 until 30<sup>th</sup> of July 2020.

288

### 289 **ETHICS**

290 The trial will abide by the principles of the World Medical Association Declaration of Helsinki (1964)  
291 and the Tokyo (1975), Venice (1983), Hong Kong (1989) and South Africa (1996), the Office of  
292 Human Research Protections (OHRP) Common Rule, 45 CFR 46 and General Data Protection  
293 Regulations (GDPR), accompanied by UK Data Protection Act (2018).

294 Ethical approval has been sought in each participating country according to country specific  
295 procedures. The protocol has gained favourable opinion from the Multicentre Research Ethics  
296 Committee in the UK and from relevant ethics committees for each participating centre. TOPS  
297 Protocol Version 1.1 (of 02 November 2009) was approved by UK ethics on 8 January 2010, the  
298 Protocol Version 4.0 (of 26 August 2015) was approved by UK ethics on 01 October 2015 and the  
299 Protocol Version 5.0 (of 22 August 2018) was approved by UK ethics on 18 November 2018. A

300 summary of substantial protocol amendments and relevant ethics committees is provided in  
301 Supplementary Material No. 5.

302

## 303 **DISSEMINATION**

304 Following completion of the study, the Principal Investigator is expected to publish the results of this  
305 research in a peer-reviewed scientific journal. According to the National Institute of Health (NIH)  
306 Public Access Policy, all journal articles arising from this NIH funded trial will be submitted to the  
307 digital archive PubMed Central. Trial investigators have the right and responsibility to communicate  
308 their findings to the scientific community and to the public. Findings of the trial will also be presented  
309 at National and International meetings of relevant professional bodies and research groups. Reports  
310 will also be posted on the WHO website (www.who.org) craniofacial section. Access to clinical data  
311 sets within speech, genetic, surgical and other fields will be available to others following the  
312 acceptance for publication of the main findings from the final dataset. Requests to access data will  
313 be subject to participant confidentiality concerns, and to contemporary NIH guidance on data-sharing  
314 plans.

315

### 316 **Author affiliations**

317 <sup>1a</sup> The University of Manchester, School of Medical Sciences, Division of Dentistry, Manchester M13  
318 9PL, UK.

319 <sup>1b</sup> Manchester Centre for Audiology and Deafness, School of Health Sciences, University of  
320 Manchester and the Manchester Academic Health Science Centre, UK

321 <sup>1c</sup> Division of Evolution & Genomic Sciences, University of Manchester and Manchester Centre for  
322 Genomic Medicine, Manchester University NHS Foundation Trust, St Marys Hospital, Oxford  
323 Road, Manchester, M13 9WL, UK

324 <sup>2</sup> Division of Speech & Language Pathology, Karolinska Institute, Functional Area Speech &  
325 Language Pathology, Karolinska University Hospital, F67 141 86 Stockholm, Sweden

326 <sup>3</sup> Institute of Neuroscience and Physiology, Speech and Language Pathology Unit, Department of  
327 Rehabilitation and Health, Sahlgrenska academy at University of Gothenburg, SE 405 30 Göteborg,  
328 Sweden

329 <sup>4</sup> Department of Nordic Studies and Linguistics, University of Copenhagen, Emit Holms Kanal 2  
330 2300 Copenhagen, Denmark

331 <sup>5</sup>Facu Faculdade de Odontologia de Bauru, Hospital de Reabilitação de Anomalias Craniofaciais  
332 Universidade de São Paulo, Bauru-SP, Brasil

333 <sup>6</sup>Clinical Trials Research Centre, University of Liverpool, Liverpool, L12 2AP.

334

TOPS Trial Protocol paper\_V11.0 05 02 2019.docx

**Contributors** William Shaw, the Chief Investigator, and Gunvor Semb conceived the trial as an extension of the Scandleft Trials and developed the first version of the protocol with Anette Lohmander, Elisabeth Willadsen, Christina Persson, Paula Williamson and Carrol Gambles. Jill Clayton-Smith developed the genetic aspects of the protocol and Inge Kiemle Trindade provided logistic advice for extension of the study to Brazil. Nicola Harman and Dieter Weichart contributed to coordination and implementation of the study, and revised and finalised the study protocol and Kevin J Munro and Elizabeth J Conroy participated in writing the protocol. All authors reviewed and approved this manuscript.

**Acknowledgments** The authors acknowledge our partners in cleft care centres in UK, Scandinavia and Brazil for participating in data collection during various stages of the TOPS trial.

Kevin J Munro is supported by the NIHR Manchester Biomedical research Centre

**Website** [WWW.tops.trial.org.uk](http://WWW.tops.trial.org.uk)

### **Funding statement**

This publication was made possible by Grants Number R21DE15128, U01DE018664 and U01DE018837 from the National Institute of Dental and Craniofacial Research (NIDCR). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIDCR.

### **Sponsorship**

TOPS trial is sponsored by the University of Manchester (Directorate of Research and Business Support Services, Chrissie Building, Oxford Road, Manchester M13 9PL Email: [clinicaltrials@manchester.ac.uk](mailto:clinicaltrials@manchester.ac.uk)). The sponsor is responsible for the overall conduct of the study and regulatory submissions. The sponsor has delegated some of its responsibility to the Data Coordinating Centre (Clinical Trials Research Centre, University of Liverpool, Institute of Child Health, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP- UK email: [tops.trial@liverpool.ac.uk](mailto:tops.trial@liverpool.ac.uk))

360

**Competing interests statement** None declared.

**Patient consent** Obtained.

**Provenance and peer review:** Not commissioned; peer reviewed for ethical and funding approval.

**Data sharing statement:** All the data used in this project will be generated directly as a result of the project, without any pre-existing data being used. All data generated during the project will be made available.

**Open Access:** this is an open Access article distributed in accordance with the creative Commons Attribution non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

<http://creativecommons.org/licenses/by-nc/4.0/>

1  
2  
3  
4 372 <http://dx.doi.org/10.1136/bmjopen-2016-011188>

5  
6 373

7  
8 374

9  
10 375 **REFERENCES**

- 11  
12 376 1. Tanaka SA, Mahabir RC, Jupiter DC, Menezes JM. Updating the Epidemiology of Isolated Cleft Palate.  
13 377 *Plast Reconstr Surg.* 2013;131(4):650e-2e.
- 14 378 2. Peterson-Falzone S. Optimal age for palatoplasty to facilitate normal speech development: What is  
15 379 the evidence? In: Berkowitz S, editor. *Cleft Lip and Palate.* Berlin: Springer; 2006. p. 691-700.
- 16 380 3. Hellquist R, Ponten B, Skoog T. The influence of cleft length and palatoplasty on the dental arch and  
17 381 the deciduous occlusion in cases of clefts of the secondary palate. *Scandinavian journal of plastic and*  
18 382 *reconstructive surgery.* 1978;12(1):45-54.
- 19 383 4. Friede H, Persson EC, Lilja J, Elander A, Lohmander-Agerskov A, Soderpalm E. Maxillary dental arch  
20 384 and occlusion in patients with repaired clefts of the secondary palate. Influence of push back palatal surgery.  
21 385 *Scandinavian journal of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk*  
22 386 *forening [and] Nordisk klubb for handkirurgi.* 1993;27(4):297-305.
- 23 387 5. Nystrom M, Ranta R. Effect of timing and method of closure of isolated cleft palate on development  
24 388 of dental arches from 3 to 6 years of age. *European journal of orthodontics.* 1994;16(5):377-83.
- 25 389 6. Friede H, Enocson L, Moller M, Owman-Moll P. Maxillary dental arch and occlusion in repaired clefts  
26 390 of the secondary palate: influence of surgical closure with minimal denudation of bone. *Scandinavian journal*  
27 391 *of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk forening [and] Nordisk klubb*  
28 392 *for handkirurgi.* 2000;34(3):213-8.
- 29 393 7. Dorf DS, Curtin JW. Early cleft palate repair and speech outcome. *Plast Reconstr Surg.* 1982;70(1):74-  
30 394 81.
- 31 395 8. Chapman KL, Hardin-Jones MA, Goldstein JA, Halter KA, Havlik RJ, Schulte J. Timing of palatal surgery  
32 396 and speech outcome. *The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-*  
33 397 *Craniofacial Association.* 2008;45(3):297-308.
- 34 398 9. Chapman KL, Willadsen E. The Development of Speech in Children with Cleft Palate. *Cleft Palate*  
35 399 *Speech: Assessment and Intervention.* 2011:23-40.
- 36 400 10. Jones DL. Timing of palatoplasty and speech. 2016. In: *Comprehensive Cleft Care [Internet].* Taylor &  
37 401 Francis Group, LLC; [521-6].
- 38 402 11. Semb G, Enemark H, Friede H, Paulin G, Lilja J, Rautio J, et al. Scandcleft randomised trials of primary  
39 403 surgery for unilateral cleft lip and palate: 1. Planning and management. *Journal of plastic surgery and hand*  
40 404 *surgery.* 2017;51(1):2-13.
- 41 405 12. Lohmander A, Willadsen E, Persson C, Henningsson G, Bowden M, Hutter B. Methodology for  
42 406 speech assessment in the scandcleft project - An international randomized clinical trial on palatal surgery:  
43 407 Experiences from a pilot study. *Cleft Palate-craniofacial Journal.* 2009;46(4):347-62.
- 44 408 13. Bannister P, Lindberg N, Jeppesen K, Elfving-Little U, Semmingsen AM, Paganini A, et al. Scandcleft  
45 409 randomised trials of primary surgery for unilateral cleft lip and palate: 3. Descriptive study of postoperative  
46 410 nursing care following first stage cleft closure. *Journal of plastic surgery and hand surgery.* 2017;51(1):21-6.
- 47 411 14. Feragen KB, Rumsey N, Heliövaara A, Boysen BM, Johannessen EC, Havstam C, et al. Scandcleft  
48 412 randomised trials of primary surgery for unilateral cleft lip and Palate: 9. Parental report of social and  
49 413 emotional experiences related to their 5-year-old child's cleft diagnosis. *Journal of plastic surgery and hand*  
50 414 *surgery.* 2017;51(1):73-80.
- 51 415 15. Feragen KB, Semb G, Heliövaara A, Lohmander A, Johannessen EC, Boysen BM, et al. Scandcleft  
52 416 randomised trials of primary surgery for unilateral cleft lip and palate: 10. Parental perceptions of  
53 417 appearance and treatment outcomes in their 5-year-old child. *Journal of plastic surgery and hand surgery.*  
54 418 2017;51(1):81-7.




TOPS Trial Protocol paper\_V11.0 05 02 2019.docx

- 1  
2  
3 419 16. Heliovaara A, Kuseler A, Skaare P, Shaw W, Molsted K, Karsten A, et al. Scandcleft randomised trials  
4 420 of primary surgery for unilateral cleft lip and palate: 6. Dental arch relationships in 5 year-olds. Journal of  
5 421 plastic surgery and hand surgery. 2017;51(1):52-7.  
6 422 17. Karsten A, Marcusson A, Hurmerinta K, Heliovaara A, Kuseler A, Skaare P, et al. Scandcleft  
7 423 randomised trials of primary surgery for unilateral cleft lip and palate: 7. Occlusion in 5 year-olds according  
8 424 to the Huddart and Bodenham index. Journal of plastic surgery and hand surgery. 2017;51(1):58-63.  
9 425 18. Lohmander A, Persson C, Willadsen E, Lundeborg I, Alaluusua S, Aukner R, et al. Scandcleft  
10 426 randomised trials of primary surgery for unilateral cleft lip and palate: 4. Speech outcomes in 5-year-olds -  
11 427 velopharyngeal competency and hypernasality. Journal of plastic surgery and hand surgery. 2017;51(1):27-  
12 428 37.  
13 429 19. Molsted K, Humerinta K, Kuseler A, Skaare P, Bellardie H, Shaw W, et al. Scandcleft randomised trials  
14 430 of primary surgery for unilateral cleft lip and palate: 8. Assessing naso-labial appearance in 5-year-olds - a  
15 431 preliminary study. Journal of plastic surgery and hand surgery. 2017;51(1):64-72.  
16 432 20. Rautio J, Andersen M, Bolund S, Hukki J, Vindenes H, Davenport P, et al. Scandcleft randomised trials  
17 433 of primary surgery for unilateral cleft lip and palate: 2. Surgical results. Journal of plastic surgery and hand  
18 434 surgery. 2017;51(1):14-20.  
19 435 21. Shaw W, Semb G. The Scandcleft randomised trials of primary surgery for unilateral cleft lip and  
20 436 palate: 11. What next? Journal of plastic surgery and hand surgery. 2017;51(1):88-93.  
21 437 22. Willadsen E, Lohmander A, Persson C, Lundeborg I, Alaluusua S, Aukner R, et al. Scandcleft  
22 438 randomised trials of primary surgery for unilateral cleft lip and palate: 5. Speech outcomes in 5-year-olds -  
23 439 consonant proficiency and errors. Journal of plastic surgery and hand surgery. 2017;51(1):38-51.  
24 440 23. Sommerlad BC. A technique for cleft palate repair. *Plast Reconstr Surg*. 2003;112(6):1542-8.  
25 441 24. Jensen BL, Kreiborg S, Dahl E, Fogh-Andersen P. Cleft lip and palate in Denmark, 1976-1981:  
26 442 epidemiology, variability, and early somatic development. *The Cleft palate journal*. 1988;25(3):258-69.  
27 443 25. Lohmander A, Hagberg E, Persson C, Willadsen E, Lundeborg I, Davies J, et al. Validity of auditory  
28 444 perceptual assessment of velopharyngeal function and dysfunction - the VPC-Sum and the VPC-Rate. *Clinical*  
29 445 *linguistics & phonetics*. 2017:1-9.  
30 446 26. Ramsdell HL, Oller DK, Buder EH, Ethington CA, Chorna L. Identification of prelinguistic phonological  
31 447 categories. *Journal of speech, language, and hearing research : JSLHR*. 2012;55(6):1626-39.  
32 448 27. Willadsen E, Persson C, Appelbe D. A software program to assist coding of prelinguistic vocalizations  
33 449 in real time. *Clin Linguist Phon*. 2018;32(10):972-8.  
34  
35  
36  
37  
38  
39 450 28. McLeod S, Harrison LJ, McCormack J. The intelligibility in Context Scale: validity and reliability of a  
40 451 subjective rating measure. *Journal of speech, language, and hearing research : JSLHR*. 2012;55(2):648-56.  
41  
42 452 29. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for  
43 453 reporting parallel group randomized trials. *Ann Intern Med*. 2010;152(11):726-32.  
44 454 30. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference  
45 455 on Harmonisation E9 Expert Working Group. *Statistics in medicine*. 1999;18(15):1905-42.  
46 456 31. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dore C, et al. Guidelines for the Content of  
47 457 Statistical Analysis Plans in Clinical Trials. *Jama*. 2017;318(23):2337-43.

49 458

50  
51  
52 459 Word count: 368553  
54 460  
55  
56  
57  
58  
59  
60

Figure 1: Flow diagram of the TOPS Trial study design



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

**End of Follow up**

\*Infants having surgery at 12 months will have their 12 month assessment prior to surgery

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



Participant Randomisation Number

## INFORMATION FOR PARENTS

Research Trial Entitled:

### Timing Of Primary Surgery For Cleft Palate (TOPS)

This trial will assess the timing of primary surgery in children with cleft palate.

Recruiting Centre Name:

<Centre Name>

Recruiting Centre ID number:

<Centre ID>

Dear Parent,

We would like to invite your child to take part in a trial of treatment for cleft palate. Before you decide whether you would like your child to take part we would like to explain to you why the research is being done and what it would involve for you.


Please take time to read the following information carefully. Ask us if there is anything that is not clear or if you would like more information. Talk to others about the trial if you wish.

Take time to decide whether or not you wish to take part.

Thank you for reading this information sheet.

### 1. What is the purpose of this trial?

The purpose of the trial is to find the best age at which to repair a cleft palate and give the child the best possible speech. Babies with cleft palate can have their surgery done at different times, usually before they are 18 months old.



The drawings above show (a) a cleft involving the soft palate and (b) a cleft involving the soft and hard palate.



Participant Number								

Some centres prefer to repair a cleft palate when the baby is around 6 months old, others when the baby is around 12 months. However as yet, there is no reliable evidence to help surgeons decide whether one timing is better than another. The only way to find out is to make a careful comparison of different timings.

Therefore an international partnership has been formed to carry out a trial that will provide clearer evidence for selecting the timing of surgery for future babies with cleft palate. A total of 650 babies will be included in the trial.

## 2. Why has my child been invited to take part?

The TOPS Trial team at <Centre Name> is inviting all infants with cleft palate to join the trial.

## 3. Does my child have to take part?

No, the research is voluntary. It is up to you to decide. We will describe the trial and go through this information sheet, which we will then give to you. You will be given time to think about the trial. Should you decide that you would like your child to participate we will ask you to sign a consent form. You are free to withdraw your child from the trial at any time, without giving a reason. This would not affect the standard of care your child receives.

If you decide that you do not want your child to participate in the TOPS trial the care they will receive will not be affected and will be the standard care provided at <Centre Name> with your child's surgery usually taking place at suitable time between the ages of 6 and 18months.

## 4. What will happen if I choose for my child to take part?

Babies with a cleft palate taking part in the trial will be divided into two groups. One group will have surgery at 6 months and one at 12 months. All will have surgery performed according to the same well-established technique and your cleft palate team will discuss the surgery with you at a routine clinic appointment. The age group that each baby goes in to will be decided by chance using a computer system, this is called randomisation and will ensure that there are equal numbers in each of the groups.

Before the operation a full physical examination will be done and a family history will be taken. During the operation a photograph and an impression of your child's mouth (called a maxillary arch impression) will be taken and a blood sample will be collected unless this has been taken previously. If a blood sample cannot be taken at surgery we will ask your permission to take it at another suitable time, for example, when your child is having a blood sample for another reason. The blood will be used to look for genetic markers which may be associated with cleft palate, these tests are routinely performed as part of your infants care and you will be informed of the results.

In all other respects the treatment and follow-up care for babies with cleft palate will be the same for those taking part in the trial and those who are not. The records used to make the comparison are the standard follow-up records and checks that all babies with cleft palate should have, although the appointments with the speech therapist at age 1, 3, and 5 years may take 20-30 minutes longer. We would also like to take a photograph of your child and make an impression of his/her teeth when they have their 5 year follow up visit.

Participant Number								
-----------------------	--	--	--	--	--	--	--	--

1  
2  
3  
4  
5 **5. What will I have to do if my child takes part?**

6 We would like you to keep all the usual appointments made to see the cleft palate team.  
7

8  
9 **6. What are the alternatives for diagnosis or treatment?**

10 As mentioned above, there are several different timings in use, but no evidence that one is better  
11 than another.  
12

13  
14 **7. Are there any possible disadvantages and risks or side-effects of taking part?**

15 The timing and techniques in the trial are standard practice, with no known differences in risk to your  
16 child.  
17

18  
19 **8. What are the possible benefits of taking part?**

20 The results we obtain from our trial of the surgical timing are unlikely to provide any direct benefit for  
21 your baby. However we hope that these results will help our team and other teams make the best  
22 possible decisions in providing treatment for future babies. The results of the genetic tests may help  
23 to identify a specific cause for the cleft palate in your family and if so we will be able to provide you  
24 with further information and offer testing to members of your extended family.  
25

26  
27 **9. What will happen if something goes wrong?**

28 In the event that something does go wrong due to negligence then you may have grounds for legal  
29 action for compensation against <Centre Name> but you may have to pay your legal costs.  
30

31 If you have a concern about any aspect of the trial you should ask to speak to a member of the cleft  
32 team who will do their best to answer your questions (contact number below).  
33

34 The normal complaints mechanisms in place at <Centre Name> will still be available to you. Details  
35 can be obtained from the hospital.  
36

37  
38 **10. What happens if I want to withdraw my child from the trial?**

39 You may withdraw your child from the trial at any time if you wish. If you withdraw your child from  
40 the trial your child's ongoing and future care will not be affected by your decision.  
41

42  
43 **11. Will my child taking part in the trial be kept confidential?**

44 All information that is collected about you and your child during the course of the trial will be kept  
45 strictly confidential, and any information that leaves <centre name> will have your child's name and  
46 address removed so that your child cannot be recognised. However, we would like to ask your  
47 permission for a copy of the consent form, which will have your and your child's name on it, to be  
48 sent to the Data Coordinating Centre at the University of Liverpool.  
49

50 All legal requirements applying to research of this kind will be strictly adhered to.  
51

52  
53 **12. What will happen to the blood sample?**

54 This sample will be analysed to see whether there is any genetic condition that may be associated  
55 with the cleft. If changes are identified on the blood tests the findings will be discussed with you and  
56 you will be offered the opportunity to discuss them with a paediatrician or clinical geneticist, should  
57 you wish. These blood tests are part of the routine care offered by <centre name>.  
58  
59  
60



Participant Randomisation Number								
----------------------------------	--	--	--	--	--	--	--	--

The blood samples will not be stored as part of the trial and we will not use them for any other tests.

### 13. What will happen to the results of the trial?

When the last patients in the trial reach age 5, and their speech has been assessed, we will analyse the results of the trial. No matter what the conclusions are, we will present the findings at professional meetings and in the appropriate medical journals so that as many future patients as possible will benefit. Naturally, no individual children will be identified in such reports. If you would like a copy of the final trial report you can indicate so on the consent letter.

### 14. Who is organising and funding the research?

The trial has been planned by an international collaboration of cleft specialists. The Administrative Centre for the trial is the University of Manchester, UK, the Data Coordinating Centre for the trial is the University of Liverpool, UK. The Administrative Centre will be responsible for the storage of your child's maxillary/dental impressions. The Data Coordinating Centre will store the information recorded, for the trial, by your child's cleft palate team, this data together with the impressions stored at Manchester will have your child's name removed. The trial is being funded by the National Institute of Dental and Craniofacial Research in the USA.

### 15. Who has reviewed the trial?

All research is looked at by an independent group of people called a research ethics committee to protect you and your child's safety, rights, wellbeing, and dignity. This trial has been reviewed and given a favourable opinion by Yorkshire and the Humber – Leeds East Research Ethics Committee

### Contact for further information

If you would like more information about the trial please contact:

<Site Coordinator Name>

<Site coordinator Contact Number>



Participant Randomisation Number									
----------------------------------	--	--	--	--	--	--	--	--	--

**CONSENT FORM**

Research Trial Entitled: **Timing Of Primary Surgery For Cleft Palate (TOPS)**

Centre Name: **<Centre Name/s>**

Name of Researchers: **<Names of all researches in involved centres>**

**Initial box**

1. I confirm that I have read and understand the information sheet (version number 3.0, dated, 01-May-2013) for the above trial. I have had the opportunity to consider the information and ask questions and have had these answered satisfactorily.
2. I understand that the participation of my child's is voluntary and that I and my child are free to withdraw at any time, without giving any reason, without our medical care or legal rights being affected.
3. I understand that relevant sections of my child's medical notes and data collected during the trial may be looked at by individuals from the research team, representatives of the sponsor, from regulatory authorities or from the organization delivering healthcare, where it is relevant to my child participating in this research. I give permission for these individuals to have access to my child's records.
4. I agree to copies of my consent form to be sent to the Data Coordinating Centre at the University of Liverpool
5. I agree to photographs of my child being taken for the purposes of the trial.
6. I agree to audio and video recordings of my child being made for the assessment of speech development.
7. I agree to my child having impressions of their mouth and teeth (maxillary arch/dental impressions) for the purposes of the trial.
8. I agree to relevant information from routine genetic tests to be used by the trial team.
9. I agree to a small blood sample being taken during surgery, or at another appropriate time, for genetic tests if they have not already been performed.
10. I agree to be contacted by the cleft palate team using the information provided for myself and other relevant contacts or to be contacted using my NHS or national identification number where appropriate.
11. I agree to my child's GP or local physician being informed about his/her participation in the trial where appropriate.
12. I agree to take part in the above trial and I also agree for my child to take part in the above trial.
13. I agree/do not agree (delete as appropriate) to be contacted by other researchers to participate in other ethically approved studies in cleft and lip palate.
14. I would like/ would not like (delete as appropriate) a copy of the final report.

_____	_____	
Name of Child	Child's Date of Birth (dd-mm-yyyy)	
_____	_____	_____
Name of Parent/Guardian	Signature of Parent/Guardian	Date (dd-mm-yyyy)
_____	_____	_____
Name of Researcher	Signature of Researcher	Date (dd-mm-yyyy)

When completed, 2 copies need to be made, 1 for the participant, 1 for the investigator site file and the original must be kept in the medical notes. A copy of the consent form only should be faxed to the Data Coordinating Centre on +44 (0) 151 282 4721





&lt; Letter Headed Paper &gt;

Participant identifier Number

## Timing Of Primary Surgery For Cleft Palate (TOPS)- Pilot study to develop methods for speech and language assessment

### INFORMATION FOR PARENTS

Research Study Entitled: **Timing Of Primary Surgery For Cleft Palate (TOPS)-Pilot study to develop methods for speech and language assessment**

This study will assess how speech assessments of infants with cleft palate are made, the outcomes of this study will then inform data collection in another project that is exploring the timing of primary surgery in children with cleft palate.

Recruiting Centre Name: <Centre Name>

Recruiting Centre ID number: <Centre ID>

Dear Parent,

We would like to invite your child to take part in a study that is being carried out to help us find out the best way to assess speech in children with cleft palate. Before you decide whether you would like your child to take part we would like to explain to you why the research is being done and what it would involve for you.

Please take time to read the following information carefully. Ask us if there is anything that is not clear or if you would like more information. Talk to others about the study if you wish.

Take time to decide whether or not you wish to take part.

Thank you for reading this information sheet.

#### 1. What is the purpose of this study?

There are a number of ways that a child's speech can be recorded and assessed. The purpose of this study is to develop the method used to record and assess speech in children with a cleft palate. This method will then be used in another project (the TOPS trial) which aims to find out the best age at which to repair a cleft palate in order to give the child the best possible speech.

#### 2. Why has my child been invited to take part?

The TOPS speech therapist at <Centre Name> is inviting all infants and children, aged between 10 and 14 months, 34 and 46 months and 58 and 70 months, to take part in this pilot study. Your child does not need to have a cleft palate for to take part.

#### 3. Does my child have to take part?

No, the research is voluntary. It is up to you to decide whether you take part. We will describe the study and go through this information sheet with you. You will also be given a copy of this information to take home. Should you decide that you would like your child to participate we will ask you to sign a consent form. You are free to withdraw your child from the study at any time, without giving a reason.

If you decide that you do not want your child to participate in this study the care they will receive will not be affected and will be the standard care provided at <Centre Name>.





Participant identifier Number									
-------------------------------	--	--	--	--	--	--	--	--	--

1  
2  
3  
4  
5 **4. What will happen if I choose for my child to take part?**

6  
7 ***If your child is aged 14 months or younger***

8 Your speech therapist will make an audio and video recording of a play situation between you and  
9 your child. The purpose of this recording is to analyse the babbling of your child as it is known to be  
10 of importance for the language development.

11  
12  
13 ***If your child is aged 34 months or older***

14 At the visit the speech therapist will ask your child to say a number of words (between 30 and 36)  
15 that have been carefully selected to allow assessment of all aspects of your child's speech. The  
16 speech therapist will make an audio and video recording of your child saying these words, and also a  
17 recording from spontaneous speech during a play session.

18 If your child is aged 58 months or older, your child will be asked to repeat sentences and retell a  
19 story. We will also ask your child to speak into a special microphone connected to a computer. This  
20 will assess how much nasal interference there is with your child's speech. You will also be asked to  
21 complete a very short questionnaire about how understandable your child's speech is to different  
22 people.

23  
24  
25  
26 **5. What happens to the video recording?**

27 The audio/video recording of your child will be used as part of the training of your speech therapist. It  
28 will also be used to develop a training package for all of the speech and language therapists involved  
29 in the TOPS trial.

30 We are doing this so that all of the speech therapists in the TOPS trial follow the same method. We  
31 would also like to ask your permission to use this recording to help train speech therapists involved in  
32 future studies.

33  
34  
35  
36 **6. What will I have to do if my child takes part?**

37 We would like you to keep the appointment made to see your child's speech therapist, in some cases  
38 this will be a usual visit or you may be asked to come for an additional appointment.

39 Your visit will last around 40-60 minutes.

40  
41  
42  
43 **7. Are there any possible disadvantages and risks or side-effects of taking part?**

44 The speech assessment made by the speech therapist is standard practice with no known risk to your  
45 child. The audio and video recording has no known risk to your child.

46  
47  
48 **8. What are the possible benefits of taking part?**

49 Taking part in this study is unlikely to provide any direct benefit to your child. However, your child's  
50 recording will help to train speech and language therapists taking part in the TOPS trial which aims to  
51 find out if the timing of surgery for cleft palate repair influences a child's speech. The methods we  
52 develop for assessing speech may also help improve how we do future research and how speech is  
53 assessed in clinical practice.

54  
55  
56  
57 **9. What will happen if something goes wrong?**

58 In the event that something does go wrong due to negligence then you may have grounds for legal  
59 action for compensation against <Centre Name> but you may have to pay your legal costs.



&lt;Letter Headed Paper&gt;

Participant identifier Number

--	--	--	--	--	--	--	--	--	--

If you have a concern about any aspect of the pilot study you should ask to speak to a member of the cleft team who will do their best to answer your questions (contact number below).

The normal complaints mechanisms in place at <Centre Name> will still be available to you. Details can be obtained from the hospital.

#### 10. What happens if I want to withdraw my child from the study?

You may withdraw your child from the study at any time if you wish. If you withdraw your child from the study your child's ongoing and future care will not be affected by your decision. If you choose to withdraw your child from the study you may also choose for audio/video recordings already made to be destroyed.

#### 11. Will my child taking part in the study be kept confidential?

All information that is collected about you and your child during the course of the study will be kept strictly confidential, and any information that leaves <centre name> will have your child's name and address removed.

We would like to ask your permission to use the audio and video recording for the training of speech and language therapists involved in the TOPS trial and also in future studies about cleft palate. To do this, a copy will be sent to the Data Coordinating Centre in Liverpool who will store the audio and video recording securely and identified by a unique number only. We would also like to ask your permission for a copy of the consent form, which will have your and your child's name on it, to be sent to the Data Coordinating Centre at the University of Liverpool.

All legal requirements applying to research of this kind will be strictly adhered to.

#### 12. What will happen to the results of the study?

The results of the sample speech recordings made in this study will be used to standardise the method of speech sample collection across the TOPS trial. The TOPS trial will assess the effects of the timing of primary surgery for cleft palate on speech development. If you would like a copy of the final TOPS trial report you can indicate so on the consent form.

#### 13. Who is organising and funding the research?

This study and the TOPS trial have been planned by an international collaboration of cleft specialists. The Administrative Centre for the projects is the University of Manchester, UK, and the Data Coordinating Centre for the projects is the University of Liverpool, UK. The study is funded by the National Institute of Dental and Craniofacial Research in the USA.

#### 14. Who has reviewed the study?

All research is looked at by an independent group of people called a research ethics committee to protect you and your child's safety, rights, wellbeing, and dignity. This study has been reviewed and given a favourable opinion by Yorkshire and the Humber – Leeds East Research Ethics Committee.

#### Contact for further information

If you would like more information about the study please contact:

<Site Coordinator Name>

<Site coordinator Contact Number>



Participant Identifier

## Timing Of Primary Surgery For Cleft Palate (TOPS)- Pilot study to develop methods for speech and language assessment

### CONSENT FORM FOR PARENTS

Research Study Entitled: **Timing Of Primary Surgery For Cleft Palate (TOPS) Pilot study to develop methods for speech and language assessment.**

Centre Name: **<Centre Name/s>**

Name of Researchers: **<Names of all researches in involved centres>**

To be filled in by the parent/guardian

Once you have read and understood each statement **please tick (✓) and initial**

#### Agreement to take part in the study

		Tick box (✓)	Initial
1.	I confirm that I have read and understand the information sheet (version number 3.0, dated, 01-May-2013) for the above study. I have had the opportunity to consider the information and ask questions and have had these answered satisfactorily.	<input type="checkbox"/>	
2.	I understand that the participation of my child is voluntary and that I and my child are free to withdraw at any time, without giving any reason, without our medical care or legal rights being affected.	<input type="checkbox"/>	
3.	I understand that data collected during the study may be looked at by individuals from the research team for training purposes, representatives of the sponsor, from regulatory authorities or from the organization delivering healthcare, where it is relevant to my child participating in this research. I give permission for these individuals to have access to my child's records.	<input type="checkbox"/>	
4.	I agree to copies of my consent form to be sent to the Data Coordinating Centre at the University of Liverpool	<input type="checkbox"/>	
5.	I agree for the recording to be sent to the University of Liverpool	<input type="checkbox"/>	
6.	I agree to audio and video recordings of my child being made and used to train speech and language therapists participating in the TOPS trial.	<input type="checkbox"/>	
7.	I agree to audio and video recording of my child being made and used to train speech and language therapists taking part in other cleft palate research.	<input type="checkbox"/>	
8.	I agree to take part in the above study and I also agree for my child to take part in the above study.	<input type="checkbox"/>	
9.	I would like/ would not like (delete as appropriate) a copy of the final report for the TOPS trial.	<input type="checkbox"/>	

\_\_\_\_\_  
Name of Child

\_\_\_\_\_  
Child's date of birth (dd-mm-yy)

\_\_\_\_\_  
Name of Parent/Guardian

\_\_\_\_\_  
Parent signature

\_\_\_\_\_  
Date signed (dd-mm-yyyy)

\_\_\_\_\_  
Name of Researcher

\_\_\_\_\_  
Signature of Researcher

\_\_\_\_\_  
Date signed (dd-mm-yyyy)

When completed, 2 copies need to be made, 1 for the participant, 1 for the investigator site file and the original must be kept in the medical notes. A copy of the consent form only should be faxed to the Data Coordinating Centre on +44 (0) 151 282 4721

Centre Name	
-------------	--

Centre ID	
-----------	--

TOPS additional information and consent form  
V1.0 30-March-2015

## Important changes to the TOPS trial

Dear Parent,

The TOPS trial that you and your child are taking part in will assess the timing of primary surgery in children with cleft palate. We have made some changes since you agreed to be in the trial and would like to let you know about these and to check you are happy with them. There are two changes aimed at improving the data we collect about your child's speech:

1. We would like to send a questionnaire to other therapists outside of <centre name> who have provided speech therapy for your child. This questionnaire will ask how many and what type of speech therapy sessions your child has had.
2. When you attend for your child's age 5 speech follow up we will ask you to complete a short questionnaire about how well your child is understood by others. The questionnaire has 7 questions and takes about 5 minutes to complete.

These changes have been looked at and approved by an independent group of people called a research ethics committee (The Yorkshire and the Humber– Leeds East Research Ethics Committee).

Please tell us if you are happy with each of these changes, or not, by completing the section below and returning this form in the addressed envelope provided. We have included a copy of the information for you to keep.

If you would like more information about these changes before you make a decision please contact:

<Site Coordinator Name>, <Site coordinator Contact Number>

Please tick ✓ and initial in the spaces below		
	Tick (✓)	Initials
I agree to my local speech therapist being contacted about my child's speech therapy sessions.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
I am happy with the changes made to the 5 year follow up visit and understand I will be asked to complete a short, 5 minute, questionnaire when I attend.	Yes <input type="checkbox"/> No <input type="checkbox"/>	

<b>Your name</b>	
------------------	--

<b>Your signature</b>	<b>Today's Date</b>	
-----------------------	---------------------	--

<b>Your child's name</b>	<b>Your child's date of birth</b>
--------------------------	-----------------------------------

### To be completed by the research team

<b>Randomisation Number</b>						
-----------------------------	--	--	--	--	--	--

<b>Date sent/given to parent</b>	d	d	m	m	y	y	<b>Sent by (Signature)</b>
----------------------------------	---	---	---	---	---	---	----------------------------

<b>Date received at site</b>	d	d	m	m	y	y	<b>Received by (Signature)</b>
------------------------------	---	---	---	---	---	---	--------------------------------

When complete, 2 copies need to be made, 1 for the participant, 1 for the investigator site file and the original must be kept in the medical notes. A copy of the consent form only should be faxed to the  
 For peer review: <http://orcid.org/0009-0001-9224-4911>  
 Data by contacting [www.bmj.com/sites/aboutguidelines.xhtml](http://www.bmj.com/sites/aboutguidelines.xhtml)

## Supplementary Material No. 1: TOPS Trial Committees

### 1.1 Trial Management Group (TMG)

The Trial Management Group (TMG) comprises members of the Administrative and Data Coordinating Centres and representatives of the core speech group and National Institute of Dental and Craniofacial Research. The Trial Management Group is responsible for the day-to-day running and management of the trial. The Trial Management Group will meet monthly in the first instance and a minimum of four times a year, attendance at Trial Management Group meetings will be by teleconference. Other meetings will be held by teleconference call as needed. Telephone and email will be a primary means of daily communication between members of the Trial Management Group.

### 1.2 Trial Steering Committee (TSC)

The Trial Steering Committee will be composed of the trial investigators, members of the trial team at the Administrative and Data Coordinating Centres in addition to an independent chairperson and independent experts in the field of cleft palate surgery, speech therapy and biostatistics.

The role of the Trial Steering Committee is to provide overall supervision for the trial and provide advice through its independent Chairman. The ultimate decision for the continuation of the trial lies with the Trial Steering Committee. The Trial Steering Committee will meet at least annually by teleconference. Other meetings will be held by bimonthly teleconference call as needed. E-mail will be a primary means of communication between members of the Trial Steering Committee. The Trial Steering Committee may also make recommendations to the Funder who may withdraw funding of the study.

### 1.3 Data and Safety Monitoring Board (DSMB)

The composition of the Data and Safety Monitoring Board will be decided by the National Institute of Health / National Institute of Dental and Craniofacial Research (NIH/NIDCR) and the initial committee meeting will be convened prior to the trial commencing.

The Data and Safety Monitoring Board is an independent (should not be involved with the trial in any other way or have some competing interest that could impact on the trial) multidisciplinary group consisting of at least one statistician and at least one clinician that,

Supplementary Material No 1.0 V1.0 05022019

1  
2  
3 collectively, have experience in the management of children with cleft palate and in the conduct  
4 of randomised controlled trials.  
5  
6

7  
8 The Data and Safety Monitoring Board will be responsible for reviewing and assessing  
9 recruitment, interim monitoring of safety, trial conduct and external data.  
10  
11

12 The full terms of reference and roles of the Data and Safety Monitoring Board are detailed in  
13 the Data and Safety Monitoring Board Charter and a copy of the open minutes from each  
14 DSMB meeting will be provided to the Program Official at National Institute of Dental and  
15 Craniofacial Research.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Material No 2.0 V1.0 05022019

**Supplementary Material No. 2:****Ethics Approval and Summary of substantial protocol amendments****Research Ethics Committees Approval**

In the UK, the TOPS Protocol version 1.1 and accompanying consent forms and their amendments have been approved by the Multicentre Research Ethics Committee in the UK (Yorkshire and the Humber – Leeds East) on 008 January 2010.

In Brazil, approvals were gained from the Ethics in Research on Human Beings Commission (Comitê de Ética em Pesquisa em Seres Humanos) of the Hospital for Rehabilitation of Craniofacial Anomalies (Hospital de Reabilitação de Anomalias Craniofaciais Universidade da São Paulo, HRAC-USP), and from the National Ethics in Research Commission (Comissão Nacional de Ética em Pesquisa, CONEP from the Conselho Nacional de Saúde).

In Denmark, approvals were received from the Institutional Review Board for the Central Denmark Region (De Videnskabsetiske Komiteer For Region Midtjylland).

In Sweden, the ethics committee approving the TOPS Protocol was the Regional Ethical Review Board in Stockholm (Regionala Etikprövningsnämnden i Stockholm)

In Norway, the regional committee for medical and health care research ethics in South-east Norway (Regional komité for medisinsk forskningsetikk sør-øst Norge, REK sør-øst B) gave ethical approval for the TOPS project. Table 1 summarises the international approval for the TOPS protocol and subsequent amendments.

Table 1: International approval of the TOPS protocol and subsequent amendments by the national and local Research Ethics Committees

Protocol		Approval Dates				
Version No	Version Date	UK	Sweden	Denmark	Norway	Brazil
1.1	02/11/2009	08/01/2010				
2	10/03/2010	26/05/2010				
2.1	06/09/2010	28/09/2010	18/11/2010	04/07/2011	20/09/2011	11/03/2011, 27/04/2011, 10/05/2011 *
3	01/05/2013	27/06/2013	11/02/2014	09/05/2014	18/12/2013	26/08/2014
4	26/08/2015	01/10/2015	22/12/2015	09/11/2016	12/08/2016	06/11/2016
5	22/08/2018	16/11/2018	03/01/2019	TBC	TBC	TBC

\* Local REC approval followed by the national REC approval in Brazil

TBC: to be confirmed

Supplementary Material No 2.0 V1.0 05022019

### **TOPS Protocol Version 2.0 (10 Mar 2010)**

There were major amendments from version 1.0 to version 2.0, as summarised below.

The secondary outcomes of the trial have been amended to include growth at age 12 months, which will be assessed by heel to crown length, nude weight and occipitofrontal circumference.

In addition, total speech and language intervention together with total speech therapy will be assessed at age 3 and age 5 years.

The wording of the postoperative complications outcome has been amended to “Postoperative/long term complications: infection, wound dehiscence and fistula”.

The TOPS protocol has been amended to include a pilot speech study, which will allow the training of speech therapists, involved in the TOPS trial, in the collection of a speech sample. The amendment requests that sample speech recordings are made in children with a cleft palate. Between 1 and 5 recordings will be made for each of the three age groups: 10-12 months, 34-38 months, 58-62 months. The number of recordings made will depend upon the experience of the speech therapists. A set of additional parent information sheets and consent forms have been included for parents and children who would like to participate in this pilot study.

### **TOPS Protocol Version 3.0 (01 May 2013)**

There were major amendments to V3.0. Key changes are summarised below:

The timing of adverse event reporting was clarified so that adverse events taking place in the 30 day post-operative period only were reported. Unanticipated problems will continue to be reported throughout the full trial duration.

Changes were made into the audiology assessments. After discussion with the OM8-30 questionnaire, developer concerns were raised about the version control and validation of the questionnaire. The OM8-30 questionnaire for the assessment for glue ear will no longer be used.

The inclusion/exclusion criteria was amended. Participants may now be included in the trial if they have Van Der Woude syndrome, as this syndrome is not considered to have an impact on development or speech and language. The exclusion criteria now states:

Infants with syndromic cleft palate (except Van der Woude syndrome, which can be included if hearing is not affected) or severe developmental delay.

Initially it was planned for teams to make follow up phone calls with participants at age 2 and 4 years. However, patients are regularly seen in clinic and so this was no longer considered necessary.



Supplementary Material No 2.0 V1.0 05022019

To help reduce the burden to sites data entry will now be completed centrally at the Data Coordinating Centre and this has been clarified in the protocol.

Other changes included amendments to the parent information sheets and consent forms (PISC) format to help ensure that the correct version (pilot study or main trial) was used. The PISC was also amended to reflect the changes to assessments and follow up telephone calls and to include an optional item for parents to consent to be contacted by other researchers regarding related research.

**TOPS Protocol Version 4.0 (26 Aug 2015)** The key changes introduced with major amendments from V3.0 to V4.0 were a very short questionnaire for the participants' parents (ICS (Intelligibility in context scale) questionnaire) and a new supplementary Parent Information and Consent form to arrange for consent to collect information using the ICS questionnaire. Furthermore, changes were made to the Pilot Parent Information and Consent form and there were also modifications to the secondary outcome measures. Finally, changes were made to the section of the protocol covering indemnity. Please see a brief summary of the changes listed below:

1. Intelligibility in context scale (ICS) questionnaire added to the speech assessments at 5 years
2. New supplementary Parent Information and Consent form, asking for consent to collect data using ICS and from local speech therapists
3. Pilot Parent Information and Consent form was amended, it now also covers collection of data using ICS and nasometer at 5 years, and includes an additional consent clause #5, stating that recordings will be sent to the Data Coordinating Centre in Liverpool.
4. Changes to secondary outcomes summarised:
  - i. Change of secondary outcome "Velopharyngeal composite score summary at age 3 years and 5 years", to "Velopharyngeal composite score summary at 5 years", as VPC-sum at 3 years is no longer possible (because this measure was recently found not to be reliable with 3year olds).
  - ii. Addition of detail to definition of secondary outcome measures No. 38: the details added now show the components of the outcome measures; The provision of detail made it necessary to split the outcome measure "Articulation" into two outcome measures: "Articulation at age 3 years" and "Articulation at age 5 years", as these are assessed in different ways; Also, the outcome measure "Audiological assessment (audiometry and tympanometry)" has now been split into "Hearing level" and "Middle ear function". While this addition of detail results in an increase of the number of secondary outcome measures listed, the actual outcome measures No. 3-8 have not changed since the last version of the protocol;
  - iii. Removal of the two secondary outcome measures "Total speech and language therapist intervention at age 3 and age 5 years" and "Total speech therapy sessions at age 3 and age 5 years" as these are recorded as background data, and do no longer constitute secondary outcome measures.

Supplementary Material No 2.0 V1.0 05022019

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17
5. Section 14, Indemnity (page 77 in protocol): Section had initially described University of Manchester as a “cosponsor for international sites” – this has been corrected and clarified in detail: the University of Manchester is the sole Sponsor for the TOPS trial. For sites in the United Kingdom, the University of Manchester as Sponsor will provide Indemnity for the trial protocol. For all other trial sites, the University of Manchester will ensure that appropriate indemnity is in place at the trial site via the contractual agreements in place. The roles and responsibilities of the Administrative Centre, Data Coordinating Centre and the trial sites involved in the TOPS trial will be defined in a Division of Responsibilities document, which will form part of any signed contractual agreements.

### 18 **TOPS Protocol Version 5.0 (22 August 2018)**

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

The key change in this substantial amendment was introduction of additional outcome measures to enable the trial team to make the best use of the existing data collected. The amendment included the addition of nasalance score to the TOPS Statistical Analysis Plan, as an exploratory analysis but not as a standalone outcome. This is to compare consistency between Speech and Language Therapist’s assessment of hypernasality and nasalance score. The additional outcome measures added to the protocol version 5.0 are summarised below along with the rationale for the changes:

- 31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47
1. VPC-rate was added because it is important to assess velopharyngeal function not only on single words but also on spontaneous speech at age 5, the most common communication condition; this is the same outcome measure as for the 3 year follow up assessment.
  2. Velopharyngeal insufficiency symptoms from single words will support the overall assessment of velopharyngeal function assessed from spontaneous speech at age 3.
  3. Assessment of oral consonant errors contributes to a better understanding of the speech errors made by children with Cleft Palate; this is the same outcome measure as for the 5 year assessment. This change will make it possible to follow the prevalence longitudinally.

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The above changes to the outcome measures will not affect site activity nor require any additional data to be collected from patients or affect their safety.

# Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised trial of palate surgery at 6 months versus 12 months of age

## Reporting checklist for protocol of a clinical trial

	Reporting Item	Page Number
Title	<a href="#">#1</a> Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a> Trial identifier and registry name. If not yet registered, name of intended registry	1
Trial registration: data set	<a href="#">#2b</a> All items from the World Health Organization Trial Registration Data Set	12
Protocol version	<a href="#">#3</a> Date and version identifier	1 & Supplementary files
Funding	<a href="#">#4</a> Sources and types of financial, material, and other support	1 and 13
Roles and responsibilities: contributorship	<a href="#">#5a</a> Names, affiliations, and roles of protocol contributors	12-13
Roles and responsibilities: sponsor contact information	<a href="#">#5b</a> Name and contact information for the trial sponsor	13
Roles and responsibilities: sponsor and funder	<a href="#">#5c</a> Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they	13 and Supplementary material No 4

will have ultimate authority over any of these activities

1			
2			
3			
4	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the
5	responsibilities:		coordinating centre, steering committee,
6	committees		endpoint adjudication committee, data
7			management team, and other individuals or
8			groups overseeing the trial, if applicable (see
9			Item 21a for data monitoring committee)
10			
11			
12			
13			
14	Background and	<a href="#">#6a</a>	Description of research question and
15	rationale		justification for undertaking the trial, including
16			summary of relevant studies (published and
17			unpublished) examining benefits and harms for
18			each intervention
19			
20			
21			
22	Background and	<a href="#">#6b</a>	Explanation for choice of comparators
23	rationale: choice of		
24	comparators		
25			
26			
27	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses
28			
29			
30	Trial design	<a href="#">#8</a>	Description of trial design including type of trial
31			(eg, parallel group, crossover, factorial, single
32			group), allocation ratio, and framework (eg,
33			superiority, equivalence, non-inferiority,
34			exploratory)
35			
36			
37			
38	Study setting	<a href="#">#9</a>	Description of study settings (eg, community
39			clinic, academic hospital) and list of countries
40			where data will be collected. Reference to
41			where list of study sites can be obtained
42			
43			
44			
45	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants.
46			If applicable, eligibility criteria for study centres
47			and individuals who will perform the
48			interventions (eg, surgeons, psychotherapists)
49			
50			
51			
52	Interventions:	<a href="#">#11a</a>	Interventions for each group with sufficient
53	description		detail to allow replication, including how and
54			when they will be administered
55			
56			
57			
58			
59			
60			

1	Interventions:	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated	NA
2	modifications		interventions for a given trial participant (eg,	
3			drug dose change in response to harms,	
4			participant request, or improving / worsening	
5			disease)	
6				
7				
8				
9	Interventions:	<a href="#">#11c</a>	Strategies to improve adherence to	4, 7 and 8
10	adherence		intervention protocols, and any procedures for	
11			monitoring adherence (eg, drug tablet return;	
12			laboratory tests)	
13				
14				
15				
16	Interventions:	<a href="#">#11d</a>	Relevant concomitant care and interventions	NA
17	concomitant care		that are permitted or prohibited during the trial	
18				
19				
20	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes,	5-7
21			including the specific measurement variable	
22			(eg, systolic blood pressure), analysis metric	
23			(eg, change from baseline, final value, time to	
24			event), method of aggregation (eg, median,	
25			proportion), and time point for each outcome.	
26			Explanation of the clinical relevance of chosen	
27			efficacy and harm outcomes is strongly	
28			recommended	
29				
30				
31				
32				
33				
34	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions	8-9 & Figure 1
35			(including any run-ins and washouts),	
36			assessments, and visits for participants. A	
37			schematic diagram is highly recommended	
38			(see Figure)	
39				
40				
41				
42	Sample size	<a href="#">#14</a>	Estimated number of participants needed to	10
43			achieve study objectives and how it was	
44			determined, including clinical and statistical	
45			assumptions supporting any sample size	
46			calculations	
47				
48				
49				
50				
51	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant	3&10
52			enrolment to reach target sample size	
53				
54				
55				
56				
57				
58				

1	Allocation:	<a href="#">#16a</a>	Method of generating the allocation sequence	4
2	sequence		(eg, computer-generated random numbers),	
3	generation		and list of any factors for stratification. To	
4			reduce predictability of a random sequence,	
5			details of any planned restriction (eg, blocking)	
6			should be provided in a separate document	
7			that is unavailable to those who enrol	
8			participants or assign interventions	
9				
10				
11				
12				
13	Allocation	<a href="#">#16b</a>	Mechanism of implementing the allocation	NA
14	concealment		sequence (eg, central telephone; sequentially	
15	mechanism		numbered, opaque, sealed envelopes),	
16			describing any steps to conceal the sequence	
17			until interventions are assigned	
18				
19				
20				
21				
22	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence,	4-5
23	implementation		who will enrol participants, and who will assign	
24			participants to interventions	
25				
26				
27	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to	5
28			interventions (eg, trial participants, care	
29			providers, outcome assessors, data analysts),	
30			and how	
31				
32				
33				
34	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which	NA/ speech
35	emergency		unblinding is permissible, and procedure for	assessments are
36	unblinding		revealing a participant's allocated intervention	carried out under
37			during the trial	blinded conditions
38				
39				
40				
41	Data collection	<a href="#">#18a</a>	Plans for assessment and collection of	9-10
42	plan		outcome, baseline, and other trial data,	
43			including any related processes to promote	
44			data quality (eg, duplicate measurements,	
45			training of assessors) and a description of	
46			study instruments (eg, questionnaires,	
47			laboratory tests) along with their reliability and	
48			validity, if known. Reference to where data	
49			collection forms can be found, if not in the	
50			protocol	
51				
52				
53				
54				
55				
56				
57				
58				

1	Data collection	<a href="#">#18b</a>	Plans to promote participant retention and	10 and Text box 1
2	plan: retention		complete follow-up, including list of any	
3			outcome data to be collected for participants	
4			who discontinue or deviate from intervention	
5			protocols	
6				
7				
8				
9	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and	10
10			storage, including any related processes to	
11			promote data quality (eg, double data entry;	
12			range checks for data values). Reference to	
13			where details of data management procedures	
14			can be found, if not in the protocol	
15				
16				
17				
18				
19	Statistics:	<a href="#">#20a</a>	Statistical methods for analysing primary and	11
20	outcomes		secondary outcomes. Reference to where	
21			other details of the statistical analysis plan can	
22			be found, if not in the protocol	
23				
24				
25				
26	Statistics:	<a href="#">#20b</a>	Methods for any additional analyses (eg,	11 and 12
27	additional analyses		subgroup and adjusted analyses)	
28				
29				
30	Statistics: analysis	<a href="#">#20c</a>	Definition of analysis population relating to	11 and 12
31	population and		protocol non-adherence (eg, as randomised	
32	missing data		analysis), and any statistical methods to	
33			handle missing data (eg, multiple imputation)	
34				
35				
36	Data monitoring:	<a href="#">#21a</a>	Composition of data monitoring committee	12 and
37	formal committee		(DMC); summary of its role and reporting	Supplementary
38			structure; statement of whether it is	material No 1
39			independent from the sponsor and competing	
40			interests; and reference to where further	
41			details about its charter can be found, if not in	
42			the protocol. Alternatively, an explanation of	
43			why a DMC is not needed	
44				
45				
46				
47				
48				
49	Data monitoring:	<a href="#">#21b</a>	Description of any interim analyses and	12 and
50	interim analysis		stopping guidelines, including who will have	Supplementary
51			access to these interim results and make the	Material No 1
52			final decision to terminate the trial	
53				
54				
55				
56				
57				
58				

1	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	8, 12 and Supplementary Material No 1
2				
3				
4				
5				
6				
7				
8	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	11 and Supplementary Material No 4
9				
10				
11				
12				
13				
14	Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	1, 1 and Supplementary Material No 5
15				
16				
17				
18				
19				
20	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	Supplementary Material No 5
21				
22				
23				
24				
25				
26				
27				
28	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4 and supplementary Materials No 1, 2 and 3
29				
30				
31				
32				
33	Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	Supplementary Materials 2 and 3
34				
35				
36				
37				
38				
39	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12 & Supplementary Materials No 1 and 2
40				
41				
42				
43				
44				
45	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	13
46				
47				
48				
49				
50				
51	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	12-13
52				
53				
54				
55				
56				
57				
58				



1	Ancillary and post	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial	NA
2	trial care		care, and for compensation to those who	
3			suffer harm from trial participation	
4				
5				
6	Dissemination	<a href="#">#31a</a>	Plans for investigators and sponsor to	12
7	policy: trial results		communicate trial results to participants,	
8			healthcare professionals, the public, and other	
9			relevant groups (eg, via publication, reporting	
10			in results databases, or other data sharing	
11			arrangements), including any publication	
12			restrictions	
13				
14				
15				
16				
17	Dissemination	<a href="#">#31b</a>	Authorship eligibility guidelines and any	12
18	policy: authorship		intended use of professional writers	
19				
20				
21	Dissemination	<a href="#">#31c</a>	Plans, if any, for granting public access to the	12
22	policy: reproducible		full protocol, participant-level dataset, and	
23	research		statistical code	
24				
25				
26				
27	Informed consent	<a href="#">#32</a>	Model consent form and other related	Supplementary
28	materials		documentation given to participants and	Materials No 1, 2 and
29			authorised surrogates	3
30				
31				
32	Biological	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and	4, 10 and
33	specimens		storage of biological specimens for genetic or	Supplementary
34			molecular analysis in the current trial and for	materials No 1
35			future use in ancillary studies, if applicable	
36				
37				
38				

39 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-  
 40 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made  
 41 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58

# BMJ Open

## Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised trial of palate surgery at 6 months versus 12 months of age

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029780.R1
Article Type:	Protocol
Date Submitted by the Author:	16-May-2019
Complete List of Authors:	Shaw, William; University of Manchester, School of Medical Sciences Semb, Gunvor; University of Manchester Faculty of Biology, Medicine and Health, Division of Dentistry Lohmander, Anette; Division of Speech & Language Pathology, Karolinska Institute, Functional Area Speech & Language Pathology, Persson, Christina; Goteborgs universitet Institutionen for neurovetenskap och fysiologi, Department of Rehabilitation and Health, Sahlgrenska academy Willadsen, Elisabeth; University of Copenhagen, Department of Nordic Studies and Linguistics Clayton-Smith, Jill; University of Manchester Faculty of Biology, Medicine and Health, Division of Evolution & Genomic Sciences Trindade, Inge; 5Facu Faculdade de Odontologia de Bauru,, Hospital de Reabilitação de Anomalias Craniofaciais Universidade de São Paulo, Munro, Kevin; The University of Manchester, Manchester Centre for Audiology and Deafness, School of Health Sciences, Gamble, Carrol; University of Liverpool, Clinical Trials Research Centre Harman, Nicola; University of Liverpool, Clinical Trials Research Centre Conroy, Elizabeth; University of Liverpool, Clinical Trials Research Centre Weichart, Dieter; The University of Manchester Faculty of Biology Medicine and Health, Division of Dentistry Williamson, Paula ; University of Liverpool, Clinical Trials Research Centre
<b>Primary Subject Heading</b>:	Dentistry and oral medicine
Secondary Subject Heading:	Surgery, Research methods, Paediatrics, Ear, nose and throat/otolaryngology, Communication
Keywords:	unilateral cleft palate, randomised clinical trial, palatal surgery, velopharyngeal function, syllable inventory, Sommerlad technique

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# 1 **Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised** 2 **trial of palate surgery at 6 months versus 12 months of age**

3 **Authors:** William Shaw<sup>1a</sup>, Gunvor Semb<sup>1a</sup>, Anette Lohmander<sup>2</sup>, Christina Persson<sup>3</sup>, Elisabeth  
4 Willadsen<sup>4</sup>, Jill Clayton-Smith<sup>1c</sup>, Inge Kiemle Trindade<sup>5</sup>, Kevin J Munro<sup>1b</sup>, Carrol Gamble<sup>6</sup>, Nicola  
5 L Harman<sup>6</sup>, Elizabeth J Conroy<sup>6</sup>, Dieter Weichert<sup>1a</sup>, and Paula Williamson<sup>6</sup>

6 Correspondence to Professor William Shaw, The University of Manchester, Division of Dentistry,  
7 Coupland 3 Building, Manchester M13 9PL email: [bill.shaw@manchester.ac.uk](mailto:bill.shaw@manchester.ac.uk)

## 9 **ABSTRACT**

10 **Introduction:** Cleft palate is amongst the most common birth abnormalities. The success of primary  
11 surgery in the early months of life is crucial for successful feeding, speech, hearing, dental  
12 development and facial growth. Over recent decades, age at palatal surgery in infancy has reduced.  
13 This has led to palatal closure in one-stage procedures being carried out around the age of 12 months,  
14 but in some cases as early as 6 months. The primary objective of the TOPS trial is to determine  
15 whether surgery for cleft palate performed at 6 or 12 months of age is most beneficial for speech  
16 outcomes.

17 **Methods and analysis:** Infants with a diagnosis of non-syndromic isolated cleft palate will be  
18 randomised to receive standardised primary surgery (Sommerlad technique) for closure of the cleft  
19 at either 6 months or 12 months, corrected for gestational age. The primary outcome will be perceived  
20 insufficient velopharyngeal function at 5 years of age. Secondary outcomes measured across 12  
21 months, 3 and 5 years will include growth, safety of the procedure, dentofacial development, speech,  
22 hearing level and middle ear function. Video and audio recordings of speech will be collected in a  
23 standardised age-appropriate manner and analysed independently by multiple speech and language  
24 therapists (SLTs). The trial aims to recruit and follow up 300 participants per arm. Data will be  
25 analysed according to the intention to treat principle using a 5% significance level. All analyses will  
26 be pre-specified within a full and detailed statistical analysis plan.

27 **Ethics and dissemination:** Ethical approval has been sought in each participating country according  
28 to country specific procedures. Trial results will be presented at conferences, published in peer-  
29 reviewed journals and disseminated through relevant patient support groups.

30 **Protocol version 5.0 22<sup>nd</sup> August 2018**

31 **Registration details:** ClinicalTrials.gov Identifier NCT00993551.

32 **Funding:** US National Institutes of Health (funder reference: 5U01DE018664/1U01DE018837)

33  
34 **Keywords:** unilateral cleft palate, randomised clinical trial, TOPS, palatal surgery,  
35 velopharyngeal function, syllable inventory, Sommerlad technique

## Strengths and limitations of the study

- International trial covering speech development in children across Scandinavia, the UK, and Brazil
- Surgical repair was calibrated across surgeons who were all trained in the Sommerlad technique.
- Longitudinal speech assessments at 12 months, 3 and 5 years will be independently analysed by multiple speech and language therapists whose ratings will be calibrated on practice recordings.
- Standardised assessments of additional outcomes include postoperative complications, hearing levels, middle ear function and dentofacial development.
- The study excludes co-existing conditions such as syndromic cleft palate or severe developmental delays that are known to adversely affect speech development or its assessment

## INTRODUCTION

Clefts of the lip and/or palate, occurring with an incidence of about 1 per 600 births, are among the most common birth anomalies. This trial will focus on isolated clefts of the palate, which occur with a global incidence of 4.5 per 10,000 births (1). Depending on geographic location, the prevalence of isolated clefts of the palate ranges from 1.8 to 14.6 per 10,000 (1).

The timing of palatal surgery has been a controversial issue since the 1930s (2). Traditionally, rationale for delaying hard palate surgery was partly based on the belief that postponing the trauma of palatal closure may reduce maxillary growth disturbance. However, there is little evidence that facial skeletal growth in individuals with isolated cleft palate is substantially affected by different surgical protocols, though maxillary arch form, especially transversely, may be affected (3-6).

Over recent decades, the age at which palatal surgery is carried out has reduced. This has led to one-stage palatal closure within 12 months of age at cleft units in Europe and the USA. Protagonists of early closure of the palatal cleft have proposed that since speech is a learned behaviour, the sooner an intact anatomy is created, the better (7-10). As yet however, there is no evidence that early surgery would lead to better speech development.

### Rationale

The widespread uncertainty surrounding the timing of palatal closure was reflected in the diversity of protocols currently employed by the Scandcleft Research Group, a partnership of Scandinavian and UK cleft lip and palate centres (11-22). The Scandcleft Research Group, identified this uncertainty as a priority research question for a future trial. Its aim was to determine whether, in infants with cleft palate, repair at either age 6 or at 12 months (corrected for gestational age) would achieve better speech outcomes. The design of the trial was supported by a planning grant from the National Institute of Dental and Craniofacial Research (NIDCR), a substream of the US National Institute of Health, who subsequently funded the proposed trial.

### Objectives

The aim of this project is to determine whether, in infants with isolated cleft palate, it is better to perform primary surgery at age 6 or 12 months (corrected for gestational age). Gestational age will be assessed based upon the date of the last menstrual period and the infant's date of birth (full term

78 defined as day 1 of the 40<sup>th</sup> week of pregnancy), thus taking account of prematurity. This research  
 79 will investigate the effect of the timing of surgery by assessing and comparing speech development  
 80 outcomes measured across 12 months, 3 years and 5 years. In addition, secondary outcomes include  
 81 growth, perioperative complications, dentofacial development, hearing level and middle ear function.

## 82 METHODS AND ANALYSIS

### 83 *Design*

84 Timing Of Primary Surgery for cleft palate (TOPS) is an international, multi-site trial using a parallel  
 85 arm design aiming to detect whether surgery at 6 months is superior to surgery at 12 months. Infants  
 86 will be randomised to receive primary surgery for cleft palate using a standardised technique (the  
 87 Sommerlad technique (23)) at either age 6 or age 12 months (corrected for gestational age). The study  
 88 design of TOPS trial is illustrated in Figure 1.

### 89 *Setting*

90 The trial will be conducted by the cleft palate teams based in centres across the UK, Scandinavia and  
 91 Brazil. Criteria for selection of sites is based primarily on ability to enrol a high volume of patients  
 92 into the trial. A list of the TOPS trial sites is provided in Table 1. The cleft team at each centre  
 93 generally includes cleft surgeon(s), nursing staff, cleft speech and language therapist(s), clinical  
 94 geneticist(s)/paediatrician(s), audiologist(s), orthodontist(s) and psychologist(s)/social worker(s)

95 **Table 1: TOPS trial clinical sites**

Country	Sites
<b>Brazil</b>	University of São Paulo (HRAC Bauru)
<b>Denmark</b>	Copenhagen Cleft Palate Centre / Århus Speech and Hearing Institute
<b>Norway</b>	Oslo University Hospital
	Helse Bergen HF
<b>Sweden</b>	Malmö University Hospital
	Göteborg University
	Karolinska University Hospital (Stockholm)
	University of Linköping
	Umeå University
<b>United Kingdom</b>	Uppsala University
	Royal Manchester Children's Hospital
	Alder Hey Children's NHS Foundation Trust
	Royal Belfast Hospital for Sick Children
	Birmingham Children's Hospital
	Royal Victoria Infirmary, Newcastle
	University Hospitals Bristol NHS Foundation Trust
	Morrison Hospital, Abertawe Bro Morgannwg University Hospital Board, Swansea
	Leeds General Infirmary
	Royal Hospital for Sick Children, Glasgow
	Royal Hospital for Sick Children, Edinburgh
Salisbury NHS Foundation Trust	
The Children's Hospital, John Radcliffe Hospital, Oxford	

## 96 ***Eligibility criteria***

97 All infants referred to the participating specialised cleft lip and palate centres are eligible to enter the  
98 trial if they meet the following inclusion and none of the exclusion criteria:

- 99 a. isolated cleft palate;
- 100 b. medically fit for surgery at 6 months, corrected for gestational age;
- 101 c. Written informed proxy consent;
- 102 d. One parent/carer must be a native language speaker of the majority language in the country  
103 of residence.

104 Infants with any of the following will be excluded from the study:

- 105 a. Consent not obtained;
- 106 b. Infants with severe developmental delay (as measured on DENVER II) or syndromic cleft  
107 palate (except Van der Woude syndrome, which can be included if hearing is not affected)  
108 will be excluded;
- 109 c. Congenital sensorineural hearing loss or structural middle ear anomalies;
- 110 d. Sommerlad technique could not be performed due to variation in the anatomical presentation;
- 111 e. Infants presenting with submucous cleft palate (defined by the classical triad of signs, bifid  
112 uvula, bony defect of the hard palate, muscular diastasis, as described by Jensen et al. (24))
- 113 f. Where the language spoken at home by at least one parent is not the majority language in the  
114 country of residence.

115 Since not all syndromic disorders will present prior to recruitment, all participants will undergo  
116 genetic testing to exclude chromosome abnormalities at the time of surgery. If a chromosome  
117 abnormality or another genetic syndrome is identified later in the study the data for these participants  
118 will be analysed separately. The same will apply if the participant fails the DENVER II  
119 developmental test at 3 year follow up.

## 120 ***Consent***

121 Informed consent will be sought from the infant's parent/guardian by a member of the local trial  
122 team, and families who decline to participate will receive surgery in line with the hospital's current  
123 practice together with the same level of care and support as families participating in the trial. Consent  
124 forms used in the TOPS trial in the UK are shown in Supplementary Materials Nos. 1, 2 and 3; these  
125 forms were adapted and translated for use in the other participating countries while maintaining key  
126 content. The final consent forms in Brazilian-Portuguese, Danish, Norwegian and Swedish were  
127 translated to English to check for accuracy and completeness. Participants can withdraw from the  
128 trial at any time without giving an explanation, and their child's care will not be affected.

129 To reduce potential burden to families, where possible, trial information will be collected at visits  
130 scheduled in line with routine visits made to the site as part of the infant's ongoing care.

## 131 ***Randomisation***

132 Infants meeting the eligibility criteria will be randomised to 6 or 12 month surgery, corrected for  
133 gestational age, in a ratio 1:1 using a minimisation routine incorporating a random element to reduce  
134 predictability. Allocations will be delivered via a password protected web-based system.

1  
2  
3 135 Every effort will be made to arrange surgery within one of week of the target date. However, surgery  
4 136 may take place up to two weeks before or four weeks after the target date. The estimated timing of  
5 137 surgery and the allowed time window for the surgery will be calculated by the online randomisation  
6 138 system and provided to the trial site at the time of randomisation.

8  
9 139 ***Interventions***

10  
11 140 The Sommerlad surgical technique (23)] will be used in all participants at 6 months or 12 months  
12 141 corrected for gestational as determined by randomisation. This technique will be standardised across  
13 142 all surgeons, including those who already use the technique, by receiving direct instruction from Mr  
14 143 Brian Sommerlad in the operating theatre. Written descriptions and a video of the surgical procedure  
15 144 will also be provided.

16  
17  
18 145 ***Blinding***

19  
20 146 The nature of the interventions prevents this trial from being blind to participants or their carers.  
21 147 However, speech and audiometry outcome assessments, at age 3 and 5 years, will be conducted and  
22 148 rated blind to the randomly allocated group.

23  
24  
25 149 ***Outcome Measures***

26  
27 150 The primary endpoint for the TOPS trial is defined as a dichotomous outcome of whether the child  
28 151 has been perceived by the SLTs to have insufficient velopharyngeal function at age 5 years or not.  
29 152 Adequate velopharyngeal function is a prerequisite for normal speech production. In children born  
30 153 with cleft palate, speech outcomes are often reported for velopharyngeal function and articulation.  
31 154 In the presence of insufficient velopharyngeal function, speech will inevitably be affected by  
32 155 symptoms such as hypernasality and nasal air emission to different degrees. In children with isolated  
33 156 cleft palate, articulation disorders occur less frequently than in children with complete cleft lip and  
34 157 palate. Insufficient perceived velopharyngeal function was therefore chosen to be the primary  
35 158 outcome and articulation outcomes as secondary outcomes. Velopharyngeal insufficiency is  
36 159 measured by velopharyngeal (VPC) sum, which is an overall score on the scale 1-6 (25). Scores  $\geq 4$   
37 160 on this scale will be considered insufficient.

38  
39  
40  
41  
42  
43 161 The secondary endpoints are summarised in Box 1 and Table 2 (Schedule of Assessments).

44  
45 162

46  
47  
48 163



164 Box 1: Secondary Endpoints

1. **Velopharyngeal function at age 5 years;**
  - a. **Velopharyngeal composite score summary (VPC sum)**
  - b. **Insufficient velopharyngeal function (VPC rate)**
2. **Velopharyngeal function at age 3 years;**
  - a. **Insufficient velopharyngeal function (VPC rate)**
  - b. **Velopharyngeal insufficiency symptoms**
3. **Canonical babbling at age 12 months:**
  - a. **Canonical babbling present**
  - b. **Canonical babbling ratio**
  - c. **Consonant inventory**
4. **Articulation at age 3 years:**
  - a. **Percent consonants correct (PCC)**
  - b. **Percent correct placement (PCP)**
  - c. **Percent correct manner (PCM)**
  - d. **Non-oral consonant errors**
  - e. **Oral consonant errors**
5. **Articulation at age 5 years:**
  - a. **Percent consonants correct (PCC)**
  - b. **Percent correct placement (PCP)**
  - c. **Percent correct manner (PCM)**
  - d. **Non-oral consonant errors**
  - e. **Oral consonant errors**
6. **Postoperative/long term complications:**
  - a. **Dehiscence**
  - b. **Infection**
  - c. **Evidence of fistula**
7. **Hearing level:**
  - a. **At 12 months**
    - i. **Abnormal Transient Otoacoustic Emission (TEOAE)**
    - ii. **Abnormal Soundfield audiometry**
  - b. **At 3 and 5 years**
    - i. **Abnormal Puretone audiometry in at least one ear**
    - ii. **Abnormal Puretone audiometry in both ears**
    - iii. **Severity of better ear (normal, mild, moderate, severe, profound)**
8. **Middle ear function**
  - a. **Flat line Tympanogram in at least one ear (12 months, 3 years, 5 years)**
  - b. **Flat line Tympanogram in both ears (12 months, 3 years, 5 years)**
9. **Dentofacial development at age 5 years:**
  - a. **Soft tissue ANB (the angle between soft tissue nasion, A point, and B point on a profile photograph)**
  - b. **Maxillary arch constriction score (using modified Huddart/Bodenham scoring system)**
10. **Growth at 12 months:**
  - a. **Nude weight**
  - b. **Crown to heel length**
  - c. **Occipitofrontal circumference**

165

166 **Speech outcome assessments**

167 To ensure quality of speech data, all sites will receive identical high quality recording equipment  
 168 (video recorder JVC-GY-HM100 series, audio recorder H4n/H5 Handy recorder, and microphone  
 169 Rode NT4/NT5) to be used at each follow-up recording according to a detailed standard operating

170 procedure. Before data collection starts at each follow up age, all SLTs will participate in a three-day  
 171 calibration meeting. Afterwards, a series of video-audio practice recordings will be completed and  
 172 quality checked. When sufficient recording quality has been reached, the site receives approval that  
 173 they can start the trial recordings. To train the SLTs who are going to perform blinded speech  
 174 assessments, a specific procedure has been developed. This includes theoretical lectures on  
 175 development of speech and language in children with cleft palate and methodological considerations  
 176 on assessment/rating, and listener training with discussions and personal feedback. Before the  
 177 assessments start, all SLTs need to pass a test with a specified level of intra- and inter-rater reliability.  
 178 They also have to pass a hearing test.

179 At 12-months of age, assessments will be done cross-linguistically. At age 3 and 5, SLT rating will  
 180 be confined to records of children sharing the SLT’s native language.

181 Vocalisations of 12-month old children will be assessed with adjusted real time listening, as described  
 182 by Ramsdell et al (26). The SLTs will listen to a 45 minutes video recording, of a play session between  
 183 the child and carer, divided in two parts (22 minutes each). The SLT will register every syllable a  
 184 child produces as canonical or not, in real time, using a software, TimeStamper, specifically  
 185 developed for this study (27). At the end of each recording, the SLT indicates if the child babbled  
 186 canonically or not, and lists the syllables the child produced with control. In this way, the variables  
 187 canonical babbling present, canonical babbling ratio, and consonant inventory are obtained.

188 The methodology for the 5-year assessment of articulation and velopharyngeal function cross-  
 189 linguistically was developed within the Scandleft study (12, 18, 22) and will be extended to include  
 190 Brazilian Portuguese. At the 5-year assessment, 36 target consonants from the TOPS single word test  
 191 will be transcribed phonetically for assessment of articulation and VPI-symptoms. Target words  
 192 include similar target sounds in the same position and with similar phonetic context across languages.  
 193 Further, repetition of sentences and continuous speech are collected, as well as nasalance scores  
 194 (Nasometer™), and parent-reported intelligibility estimates of how well their children’s speech is  
 195 understood by different listeners (Intelligibility in context scale (28)). The 3-year assessment will be  
 196 based on 30 of the 36 words used in the 5-year assessment, and target consonants will be transcribed  
 197 phonetically for assessment of articulation. Error types will be classified automatically by a  
 198 predefined script that will also allow calculation of PCC, PCP, and PCM. The VPC-rate will be rated  
 199 by SLTs from continuous speech both at age 3 and 5 years

Outcome Measures	Assessment Schedule (age is corrected for gestational age)					
	Assessments	Post-surgery		12 months	3 years	5 years
		48 hours	30 days			
Surgical Complications	Dehiscence	√	√			
	Infection	√	√			
	Evidence of Fistula		√		√	√

Table 2:

203 Schedule of Assessments

<b>Growth</b>	Nude Weight			√		
	Crown to heel length			√		
	Occipitofrontal Circumference			√		
<b>Canonical Babbling</b>	Canonical Babbling present <sup>e</sup>			√		
	Canonical Babbling ratio <sup>e</sup>			√		
	Consonant Inventory <sup>e</sup>			√		
<b>Velopharyngeal Function</b>	Velopharyngeal composite score summary (VPC-sum)					√ <sup>a,b</sup>
	Insufficient Velopharyngeal function (VPC rate)				√ <sup>c</sup>	√ <sup>d</sup>
	Velopharyngeal insufficiency Symptoms				√ <sup>a</sup>	
<b>Articulation</b>	Percent Consonant Correct (PCC) <sup>a</sup>				√	√
	Percent Correct Placement (PCP) <sup>a</sup>				√	√
	Percent Correct Manner (PCM) <sup>a</sup>				√	√
	Non-oral consonant errors <sup>a</sup>				√	√
	Oral Consonant errors <sup>a</sup>				√	√
<b>Hearing Level</b>	Abnormal Transient Otoacoustic Emission (TEOAE)			√		
	Abnormal Soundfield Audiometry			√		
	Abnormal Pure Tone Audiometry in at least one ear*				√	√
	Abnormal Pure tone Audiometry in both ears*				√	√
	Severity of better ear*				√	√
	Soundfield Audiometry*				√	√
<b>Middle Ear Function</b>	Flat Line Tympanogram in at least one ear			√	√	√
	Flat Line Tympanogram in both ear			√	√	√

<b>Dentofacial Development</b>	Soft Tissue ANB**					√
	Maxillary arch Constriction score***					√
<b>Others</b>	DENVER II Developmental Assessment****				√	
	Intelligibility in Context Scale Questionnaire for parents (ICS)					√
	Local site questionnaire*****				√	√

209

210

211

212

213

214 \*: if puretone audiometry could not be performed then Soundfield audiometry will be performed

215 \*\*: the angle between soft tissue nasion A point and B pint on a profile photograph

216 \*\*\*: maxillary arch constriction score is determined using modified Huddart/Bodenham scoring system

217 \*\*\*\*: DENVER II developmental Assessment is carried out at the time of surgery

218 \*\*\*\*\*: Local site questionnaire sent to local speech and language therapists outside TOPS research team to collect data on direct and indirect therapy given to the child in the intervals between assessment visits

219 Sources of speech assessments; a: TOPS picture naming test, b: nine word string, c: spontaneous speech, d: spontaneous speech (retelling of bus story) and e: video of play interaction.

222

## 223 Patient and Public Involvement

224 Parents of children with cleft palate were approached by their orthodontist / surgeons prior to  
 225 enrolment. Patients and their parents were not initially involved in the design of the study. However,  
 226 a representative from the Cleft Lip & Palate Association (the charity for Cleft Lip & Palate in the  
 227 UK) is a member of the Trial Steering Committee. Therefore, providing ongoing insight from a parent  
 228 perspective with regards to the execution of this study and the dissemination of results.

## 229 Data collection and management

230 Trial data will be recorded on Case Report Forms (CRFs) and identifiable only by randomisation  
 231 number. The data from completed CRFs will be entered onto the trial specific MACRO database by  
 232 the Data Manager or appropriately trained personnel at the Data Coordinating Centre.

### 233 ***Video and audio recording***

234 Once recorded, video and audio recordings will be saved onto encrypted USB drives. They will be  
235 posted to the Data Coordinating Centre where, upon receipt, they will be logged and stored onto the  
236 trial specific secure server. This server will be backed up once a day to ensure data is not lost once  
237 received. Recordings are quality checked by the Core Speech Group and/or the Trial Administrative  
238 Centre. A satisfactory recording is one that passes pre-specified quality checks on lighting, length  
239 and sound. Quality checks will be performed regularly and feedback to site will be provided on their  
240 suitability for assessment.

### 241 ***Maxillary arch impressions***

242 Maxillary arch impressions will be obtained at the time of surgery to provide a mould for plaster  
243 casts, which are sent to the TOPS Administrative Centre at the University of Manchester.

244 In addition, impressions of the maxillary and mandibular dental arches will be obtained at the 5 year  
245 follow-up appointment. Impressions are taken by a designated member of staff (usually the  
246 orthodontist) using appropriate impression material. The occlusion will be registered with a wax  
247 wafer in the position of maximal intercuspation. The study models made from the impressions will  
248 be stored at the TOPS Administrative Centre.

### 249 250 ***Photographs***

251 Intra-oral photographs will be taken at the time of surgery, and frontal and lateral photographs will  
252 be obtained at the 5-year visit. The photographs will be saved onto encrypted USBs, upon receipt by  
253 the Data Coordinating Centre they will be logged and stored onto trial specific secure hard drives.

### 254 ***Statistical analysis and sample size considerations***

#### 255 ***Proposed sample size***

256 300 patients per arm will allow a reduction in insufficient velopharyngeal function at 5 years from  
257 40% to 29% to be detected with 81% power using a chi-square test (2 sided significance test at 0.05  
258 level). The estimate of 40% was obtained from a pilot trial in 50 five year of patients, collected during  
259 the planning period for this grant application (12). To allow an approximate drop out of 10%, 648  
260 participants will be recruited. However to consider the potential impact of variability around the value  
261 of 40%, 300 patients per group would provide 80% power to detect a reduction from 30% to 20%  
262 and 76% power to detect a reduction from 20% to 12%.

263  
264 The trial enrolment, allocation, follow up and analysis will be reported using the “Consolidated  
265 Standard of Reporting Trials” (“CONSORT”) (29) and the International Conference on  
266 Harmonisation E9 guidelines (30). A full and detailed statistical analysis plan (31) will be developed  
267 prior to the final analysis of the trial. The main features of the statistical analysis plan are included  
268 here.

269 The primary analysis will be by intention-to-treat principle, as far as is practically possible using a  
270 5% significance level throughout. Rather than adjust for multiplicity of secondary outcomes, relevant

271 results from other studies already reported in the literature will be taken into account in the  
272 interpretation. The approach to formal analyses will be dependent on outcome type as follows:

- 273 • *Dichotomous outcome* will be compared between the two groups using a chi-squared test and  
274 the effect estimate will be reported in terms of the relative risk and 95% confidence interval.
- 275 • *Short ordinal outcomes* will be compared using a chi-squared test for trend.
- 276 • *Continuous and long ordinal outcomes* will be compared between the two groups using a two  
277 group t-test. The difference in means will be presented with a 95% confidence interval.

278 Baseline and operative characteristics and safety data will be presented using descriptive statistics  
279 only.

280 If the percentage of major protocol deviations exceeds 10% and the trial management group consider  
281 this analysis appropriate, a per protocol analysis in which pre-specified major protocol deviations  
282 indicate exclusion of a participant from the analysis set will be conducted.

### 283 **Trial oversight and monitoring**

284 The Trial Management Group (TMG), Trial Steering Committee (TSC) and Data Safety and  
285 Monitoring Board (DSMB) will provide ongoing oversight and will monitor accruing trial data. The  
286 roles, responsibilities and composition of each of these committees are provided in Supplementary  
287 Material No. 4. A risk assessment has been conducted and used to inform a trial specific monitoring  
288 plan agreed by the independent oversight committees.

### 289 **Trial status and timeline**

290 The overall programme commenced 13/07/2010. Applications for ethics approval were submitted  
291 10/11/2009. Recruitment to the trial commenced 13/07/2010. Participants will be followed up until  
292 30<sup>th</sup> July 2020.

293 This trial completed recruitment on 21<sup>st</sup> July 2015 and the last patient is due to attend their last visit  
294 until 30<sup>th</sup> of July 2020.

295

### 296 **ETHICS**

297 The trial will abide by the principles of the World Medical Association Declaration of Helsinki (1964)  
298 and the Tokyo (1975), Venice (1983), Hong Kong (1989) and South Africa (1996), the Office of  
299 Human Research Protections (OHRP) Common Rule, 45 CFR 46 and General Data Protection  
300 Regulations (GDPR), accompanied by UK Data Protection Act (2018).

301 Ethical approval has been sought in each participating country according to country specific  
302 procedures. The protocol has gained favourable opinion from the Multicentre Research Ethics  
303 Committee in the UK and from relevant ethics committees for each participating centre. TOPS  
304 Protocol Version 1.1 (of 02 November 2009) was approved by UK ethics on 8 January 2010, the  
305 Protocol Version 4.0 (of 26 August 2015) was approved by UK ethics on 01 October 2015 and the  
306 Protocol Version 5.0 (of 22 August 2018) was approved by UK ethics on 18 November 2018. A

307 summary of substantial protocol amendments and relevant ethics committees is provided in  
308 Supplementary Material No. 5.

309

## 310 **DISSEMINATION**

311 Following completion of the study, the Principal Investigator is expected to publish the results of this  
312 research in a peer-reviewed scientific journal. According to the National Institute of Health (NIH)  
313 Public Access Policy, all journal articles arising from this NIH funded trial will be submitted to the  
314 digital archive PubMed Central. Trial investigators have the right and responsibility to communicate  
315 their findings to the scientific community and to the public. Findings of the trial will also be presented  
316 at National and International meetings of relevant professional bodies and research groups. Reports  
317 will also be posted on the WHO website ([www.who.org](http://www.who.org)) craniofacial section. Access to clinical data  
318 sets within speech, genetic, surgical and other fields will be available to others following the  
319 acceptance for publication of the main findings from the final dataset. Requests to access data will  
320 be subject to participant confidentiality concerns, and to contemporary NIH guidance on data-sharing  
321 plans.

322

### 323 **Author affiliations**

324 <sup>1a</sup> The University of Manchester, School of Medical Sciences, Division of Dentistry, Manchester M13  
325 9PL, UK.

326 <sup>1b</sup> Manchester Centre for Audiology and Deafness, School of Health Sciences, University of  
327 Manchester and the Manchester Academic Health Science Centre, UK

328 <sup>1c</sup> Division of Evolution & Genomic Sciences, University of Manchester and Manchester Centre for  
329 Genomic Medicine, Manchester University NHS Foundation Trust, St Marys Hospital, Oxford  
330 Road, Manchester, M13 9WL, UK

331 <sup>2</sup> Division of Speech & Language Pathology, Karolinska Institute, Functional Area Speech &  
332 Language Pathology, Karolinska University Hospital, F67 141 86 Stockholm, Sweden

333 <sup>3</sup> Institute of Neuroscience and Physiology, Speech and Language Pathology Unit, Department of  
334 Rehabilitation and Health, Sahlgrenska academy at University of Gothenburg, SE 405 30 Göteborg,  
335 Sweden

336 <sup>4</sup> Department of Nordic Studies and Linguistics, University of Copenhagen, Emit Holms Kanal 2  
337 2300 Copenhagen, Denmark

338 <sup>5</sup> Faculdade de Odontologia de Bauru, Hospital de Reabilitação de Anomalias Craniofaciais  
339 Universidade de São Paulo, Bauru-SP, Brasil

340 <sup>6</sup> Clinical Trials Research Centre, University of Liverpool, Liverpool, L12 2AP.

341

1  
2  
3 342 **Contributors** William Shaw, the Chief Investigator , and Gunvor Semb conceived the trial as an  
4 343 extension of the Scandleft Trial and developed the first version of the protocol with Anette  
5 344 Lohmander, Elisabeth Willadsen, Christina Persson, Paula Williamson and Carrol Gamble. Jill  
6 345 Clayton-Smith developed the genetic aspects of the protocol and Inge Kiemle Trindade provided  
7 346 logistic advice for extension of the study to Brazil. Nicola Harman and Dieter Weichart contributed  
8 347 to coordination and implementation of the study, and revised and finalised the study protocol and  
9 348 Kevin J Munro and Elizabeth J Conroy participated in writing the protocol. All authors reviewed and  
10 349 approved this manuscript.

11  
12  
13 350 **Acknowledgments** The authors acknowledge our partners in cleft care centres in UK, Scandinavia  
14 351 and Brazil for participating in data collection during various stages of the TOPS trial.

15  
16  
17 352 Kevin J Munro is supported by the NIHR Manchester Biomedical research Centre

18  
19 353 **Website** [WWW.tops.trial.org.uk](http://WWW.tops.trial.org.uk)

#### 20 354 **Funding statement**

21  
22  
23 355 This publication was made possible by Grants Number R21DE15128, U01DE018664 and  
24 356 U01DE018837 from the National Institute of Dental and Craniofacial Research (NIDCR). Its  
25 357 contents are solely the responsibility of the authors and do not necessarily represent the official views  
26 358 of the NIDCR.

#### 27 359 **Sponsorship**

28  
29 360 TOPS trial is sponsored by the University of Manchester (Directorate of Research and Business  
30 361 Support Services, Chrtsie Building, Oxford Road, Manchester M13 9PL Email:  
31 362 [clinicaltrials@manchester.ac.uk](mailto:clinicaltrials@manchester.ac.uk)). The sponsor is responsible for the overall conduct of the study  
32 363 and regulatory submissions. The sponsor has delegated some of its responsibility to the Data  
33 364 Coordinating Centre (Clinical Trials Research Centre, University of Liverpool, Instittue of Child  
34 365 Health, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP- UK  
35 366 email:tops.trial@liverpool.ac.uk)

36  
37  
38 367

39  
40 368 **Competing interests statement** None declared.

41  
42 369 **Patient consent** Obtained.

43  
44 370 **Provenance and peer review:** Not commissioned; peer reviewed for ethical and funding approval.

45  
46 371 **Data sharing statement:** All the data used in this project will be generated directly as a result of the  
47 372 project, without any pre-existing data being used. All data generated during the project will be made  
48 373 available.

49  
50 374 **Open Access:** this is an open Access article distributed in accordance with the creative Commons  
51 375 Attribution non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,  
52 376 adapt, build upon this work non-commercially, and license their derivative works on different terms,  
53 377 provided the original work is properly cited and the use is non-commercial. See:

54  
55 378 <http://creativecommons.org/licenses/by-nc/4.0/>



379 <http://dx.doi.org/10.1136/bmjopen-2016-011188>

380

381

## 382 REFERENCES

- 383 1. Tanaka SA, Mahabir RC, Jupiter DC, Menezes JM. Updating the Epidemiology of Isolated Cleft Palate.  
384 *Plast Reconstr Surg.* 2013;131(4):650e-2e.
- 385 2. Peterson-Falzone S. Optimal age for palatoplasty to facilitate normal speech development: What is  
386 the evidence? In: Berkowitz S, editor. *Cleft Lip and Palate.* Berlin: Springer; 2006. p. 691-700.
- 387 3. Hellquist R, Ponten B, Skoog T. The influence of cleft length and palatoplasty on the dental arch and  
388 the deciduous occlusion in cases of clefts of the secondary palate. *Scandinavian journal of plastic and*  
389 *reconstructive surgery.* 1978;12(1):45-54.
- 390 4. Friede H, Persson EC, Lilja J, Elander A, Lohmander-Agerskov A, Soderpalm E. Maxillary dental arch  
391 and occlusion in patients with repaired clefts of the secondary palate. Influence of push back palatal surgery.  
392 *Scandinavian journal of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk*  
393 *forening [and] Nordisk klubb for handkirurgi.* 1993;27(4):297-305.
- 394 5. Nystrom M, Ranta R. Effect of timing and method of closure of isolated cleft palate on development  
395 of dental arches from 3 to 6 years of age. *European journal of orthodontics.* 1994;16(5):377-83.
- 396 6. Friede H, Enocson L, Moller M, Owman-Moll P. Maxillary dental arch and occlusion in repaired clefts  
397 of the secondary palate: influence of surgical closure with minimal denudation of bone. *Scandinavian journal*  
398 *of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk forening [and] Nordisk klubb*  
399 *for handkirurgi.* 2000;34(3):213-8.
- 400 7. Dorf DS, Curtin JW. Early cleft palate repair and speech outcome. *Plast Reconstr Surg.* 1982;70(1):74-  
401 81.
- 402 8. Chapman KL, Hardin-Jones MA, Goldstein JA, Halter KA, Havlik RJ, Schulte J. Timing of palatal surgery  
403 and speech outcome. *The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-*  
404 *Craniofacial Association.* 2008;45(3):297-308.
- 405 9. Chapman KL, Willadsen E. The Development of Speech in Children with Cleft Palate. *Cleft Palate*  
406 *Speech: Assessment and Intervention.* 2011:23-40.
- 407 10. Jones DL. Timing of palatoplasty and speech. 2016. In: *Comprehensive Cleft Care [Internet].* Taylor &  
408 Francis Group, LLC; [521-6].
- 409 11. Semb G, Enemark H, Friede H, Paulin G, Lilja J, Rautio J, et al. Scandcleft randomised trials of primary  
410 surgery for unilateral cleft lip and palate: 1. Planning and management. *Journal of plastic surgery and hand*  
411 *surgery.* 2017;51(1):2-13.
- 412 12. Lohmander A, Willadsen E, Persson C, Henningsson G, Bowden M, Hutter B. Methodology for  
413 speech assessment in the scandcleft project - An international randomized clinical trial on palatal surgery:  
414 Experiences from a pilot study. *Cleft Palate-craniofacial Journal.* 2009;46(4):347-62.
- 415 13. Bannister P, Lindberg N, Jeppesen K, Elfving-Little U, Semmingsen AM, Paganini A, et al. Scandcleft  
416 randomised trials of primary surgery for unilateral cleft lip and palate: 3. Descriptive study of postoperative  
417 nursing care following first stage cleft closure. *Journal of plastic surgery and hand surgery.* 2017;51(1):21-6.
- 418 14. Feragen KB, Rumsey N, Heliövaara A, Boysen BM, Johannessen EC, Havstam C, et al. Scandcleft  
419 randomised trials of primary surgery for unilateral cleft lip and Palate: 9. Parental report of social and  
420 emotional experiences related to their 5-year-old child's cleft diagnosis. *Journal of plastic surgery and hand*  
421 *surgery.* 2017;51(1):73-80.
- 422 15. Feragen KB, Semb G, Heliövaara A, Lohmander A, Johannessen EC, Boysen BM, et al. Scandcleft  
423 randomised trials of primary surgery for unilateral cleft lip and palate: 10. Parental perceptions of  
424 appearance and treatment outcomes in their 5-year-old child. *Journal of plastic surgery and hand surgery.*  
425 2017;51(1):81-7.

TOPS Trial Protocol paper\_V12.0 16 05 2019.docx


16. Heliovaara A, Kuseler A, Skaare P, Shaw W, Molsted K, Karsten A, et al. Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 6. Dental arch relationships in 5 year-olds. *Journal of plastic surgery and hand surgery*. 2017;51(1):52-7.
17. Karsten A, Marcusson A, Hurmerinta K, Heliovaara A, Kuseler A, Skaare P, et al. Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 7. Occlusion in 5 year-olds according to the Huddart and Bodenham index. *Journal of plastic surgery and hand surgery*. 2017;51(1):58-63.
18. Lohmander A, Persson C, Willadsen E, Lundeborg I, Alaluusua S, Aukner R, et al. Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 4. Speech outcomes in 5-year-olds - velopharyngeal competency and hypernasality. *Journal of plastic surgery and hand surgery*. 2017;51(1):27-37.
19. Molsted K, Humerinta K, Kuseler A, Skaare P, Bellardie H, Shaw W, et al. Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 8. Assessing naso-labial appearance in 5-year-olds - a preliminary study. *Journal of plastic surgery and hand surgery*. 2017;51(1):64-72.
20. Rautio J, Andersen M, Bolund S, Hukki J, Vindenes H, Davenport P, et al. Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 2. Surgical results. *Journal of plastic surgery and hand surgery*. 2017;51(1):14-20.
21. Shaw W, Semb G. The Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 11. What next? *Journal of plastic surgery and hand surgery*. 2017;51(1):88-93.
22. Willadsen E, Lohmander A, Persson C, Lundeborg I, Alaluusua S, Aukner R, et al. Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 5. Speech outcomes in 5-year-olds - consonant proficiency and errors. *Journal of plastic surgery and hand surgery*. 2017;51(1):38-51.
23. Sommerlad BC. A technique for cleft palate repair. *Plast Reconstr Surg*. 2003;112(6):1542-8.
24. Jensen BL, Kreiborg S, Dahl E, Fogh-Andersen P. Cleft lip and palate in Denmark, 1976-1981: epidemiology, variability, and early somatic development. *The Cleft palate journal*. 1988;25(3):258-69.
25. Lohmander A, Hagberg E, Persson C, Willadsen E, Lundeborg I, Davies J, et al. Validity of auditory perceptual assessment of velopharyngeal function and dysfunction - the VPC-Sum and the VPC-Rate. *Clinical linguistics & phonetics*. 2017:1-9.
26. Ramsdell HL, Oller DK, Buder EH, Ethington CA, Chorna L. Identification of prelinguistic phonological categories. *Journal of speech, language, and hearing research : JSLHR*. 2012;55(6):1626-39.
27. Willadsen E, Persson C, Appelbe D. A software program to assist coding of prelinguistic vocalizations in real time. *Clin Linguist Phon*. 2018;32(10):972-8.
28. McLeod S, Harrison LJ, McCormack J. The intelligibility in Context Scale: validity and reliability of a subjective rating measure. *Journal of speech, language, and hearing research : JSLHR*. 2012;55(2):648-56.
29. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med*. 2010;152(11):726-32.
30. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. *Statistics in medicine*. 1999;18(15):1905-42.
31. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dore C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *Jama*. 2017;318(23):2337-43.

465

466 Word count: 3772

467 Figure 1: flow diagram of TOPS study design

Figure 1: Flow diagram of the TOPS Trial study design



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

\*Infants having surgery at 12 months will have their 12 month assessment prior to surgery

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



&lt;Letter Headed Paper&gt;

Participant Randomisation Number

## INFORMATION FOR PARENTS

Research Trial Entitled:

### Timing Of Primary Surgery For Cleft Palate (TOPS)

This trial will assess the timing of primary surgery in children with cleft palate.

Recruiting Centre Name:

&lt;Centre Name&gt;

Recruiting Centre ID number:

&lt;Centre ID&gt;

Dear Parent,

We would like to invite your child to take part in a trial of treatment for cleft palate. Before you decide whether you would like your child to take part we would like to explain to you why the research is being done and what it would involve for you.


Please take time to read the following information carefully. Ask us if there is anything that is not clear or if you would like more information. Talk to others about the trial if you wish.

Take time to decide whether or not you wish to take part.

Thank you for reading this information sheet.

### 1. What is the purpose of this trial?

The purpose of the trial is to find the best age at which to repair a cleft palate and give the child the best possible speech. Babies with cleft palate can have their surgery done at different times, usually before they are 18 months old.



The drawings above show (a) a cleft involving the soft palate and (b) a cleft involving the soft and hard palate.



Participant Number								

Some centres prefer to repair a cleft palate when the baby is around 6 months old, others when the baby is around 12 months. However as yet, there is no reliable evidence to help surgeons decide whether one timing is better than another. The only way to find out is to make a careful comparison of different timings.

Therefore an international partnership has been formed to carry out a trial that will provide clearer evidence for selecting the timing of surgery for future babies with cleft palate. A total of 650 babies will be included in the trial.

## 2. Why has my child been invited to take part?

The TOPS Trial team at <Centre Name> is inviting all infants with cleft palate to join the trial.

## 3. Does my child have to take part?

No, the research is voluntary. It is up to you to decide. We will describe the trial and go through this information sheet, which we will then give to you. You will be given time to think about the trial. Should you decide that you would like your child to participate we will ask you to sign a consent form. You are free to withdraw your child from the trial at any time, without giving a reason. This would not affect the standard of care your child receives.

If you decide that you do not want your child to participate in the TOPS trial the care they will receive will not be affected and will be the standard care provided at <Centre Name> with your child's surgery usually taking place at suitable time between the ages of 6 and 18months.

## 4. What will happen if I choose for my child to take part?

Babies with a cleft palate taking part in the trial will be divided into two groups. One group will have surgery at 6 months and one at 12 months. All will have surgery performed according to the same well-established technique and your cleft palate team will discuss the surgery with you at a routine clinic appointment. The age group that each baby goes in to will be decided by chance using a computer system, this is called randomisation and will ensure that there are equal numbers in each of the groups.

Before the operation a full physical examination will be done and a family history will be taken. During the operation a photograph and an impression of your child's mouth (called a maxillary arch impression) will be taken and a blood sample will be collected unless this has been taken previously. If a blood sample cannot be taken at surgery we will ask your permission to take it at another suitable time, for example, when your child is having a blood sample for another reason. The blood will be used to look for genetic markers which may be associated with cleft palate, these tests are routinely performed as part of your infants care and you will be informed of the results.

In all other respects the treatment and follow-up care for babies with cleft palate will be the same for those taking part in the trial and those who are not. The records used to make the comparison are the standard follow-up records and checks that all babies with cleft palate should have, although the appointments with the speech therapist at age 1, 3, and 5 years may take 20-30 minutes longer. We would also like to take a photograph of your child and make an impression of his/her teeth when they have their 5 year follow up visit.

Participant Number								
-----------------------	--	--	--	--	--	--	--	--

## 5. What will I have to do if my child takes part?

We would like you to keep all the usual appointments made to see the cleft palate team.

## 6. What are the alternatives for diagnosis or treatment?

As mentioned above, there are several different timings in use, but no evidence that one is better than another.

## 7. Are there any possible disadvantages and risks or side-effects of taking part?

The timing and techniques in the trial are standard practice, with no known differences in risk to your child.

## 8. What are the possible benefits of taking part?

The results we obtain from our trial of the surgical timing are unlikely to provide any direct benefit for your baby. However we hope that these results will help our team and other teams make the best possible decisions in providing treatment for future babies. The results of the genetic tests may help to identify a specific cause for the cleft palate in your family and if so we will be able to provide you with further information and offer testing to members of your extended family.

## 9. What will happen if something goes wrong?

In the event that something does go wrong due to negligence then you may have grounds for legal action for compensation against <Centre Name> but you may have to pay your legal costs.

If you have a concern about any aspect of the trial you should ask to speak to a member of the cleft team who will do their best to answer your questions (contact number below).

The normal complaints mechanisms in place at <Centre Name> will still be available to you. Details can be obtained from the hospital.

## 10. What happens if I want to withdraw my child from the trial?

You may withdraw your child from the trial at any time if you wish. If you withdraw your child from the trial your child's ongoing and future care will not be affected by your decision.

## 11. Will my child taking part in the trial be kept confidential?

All information that is collected about you and your child during the course of the trial will be kept strictly confidential, and any information that leaves <centre name> will have your child's name and address removed so that your child cannot be recognised. However, we would like to ask your permission for a copy of the consent form, which will have your and your child's name on it, to be sent to the Data Coordinating Centre at the University of Liverpool.

All legal requirements applying to research of this kind will be strictly adhered to.

## 12. What will happen to the blood sample?

This sample will be analysed to see whether there is any genetic condition that may be associated with the cleft. If changes are identified on the blood tests the findings will be discussed with you and you will be offered the opportunity to discuss them with a paediatrician or clinical geneticist, should you wish. These blood tests are part of the routine care offered by <centre name>.



Participant Number								

The blood samples will not be stored as part of the trial and we will not use them for any other tests.

### 13. What will happen to the results of the trial?

When the last patients in the trial reach age 5, and their speech has been assessed, we will analyse the results of the trial. No matter what the conclusions are, we will present the findings at professional meetings and in the appropriate medical journals so that as many future patients as possible will benefit. Naturally, no individual children will be identified in such reports. If you would like a copy of the final trial report you can indicate so on the consent letter.

### 14. Who is organising and funding the research?

The trial has been planned by an international collaboration of cleft specialists. The Administrative Centre for the trial is the University of Manchester, UK, the Data Coordinating Centre for the trial is the University of Liverpool, UK. The Administrative Centre will be responsible for the storage of your child's maxillary/dental impressions. The Data Coordinating Centre will store the information recorded, for the trial, by your child's cleft palate team, this data together with the impressions stored at Manchester will have your child's name removed. The trial is being funded by the National Institute of Dental and Craniofacial Research in the USA.

### 15. Who has reviewed the trial?

All research is looked at by an independent group of people called a research ethics committee to protect you and your child's safety, rights, wellbeing, and dignity. This trial has been reviewed and given a favourable opinion by Yorkshire and the Humber – Leeds East Research Ethics Committee

### Contact for further information

If you would like more information about the trial please contact:

<Site Coordinator Name>

<Site coordinator Contact Number>







&lt; Letter Headed Paper &gt;

Participant identifier Number

## Timing Of Primary Surgery For Cleft Palate (TOPS)- Pilot study to develop methods for speech and language assessment

### INFORMATION FOR PARENTS

Research Study Entitled: **Timing Of Primary Surgery For Cleft Palate (TOPS)-Pilot study to develop methods for speech and language assessment**

This study will assess how speech assessments of infants with cleft palate are made, the outcomes of this study will then inform data collection in another project that is exploring the timing of primary surgery in children with cleft palate.

Recruiting Centre Name: <Centre Name>

Recruiting Centre ID number: <Centre ID>

Dear Parent,

We would like to invite your child to take part in a study that is being carried out to help us find out the best way to assess speech in children with cleft palate. Before you decide whether you would like your child to take part we would like to explain to you why the research is being done and what it would involve for you.

Please take time to read the following information carefully. Ask us if there is anything that is not clear or if you would like more information. Talk to others about the study if you wish.

Take time to decide whether or not you wish to take part.

Thank you for reading this information sheet.

#### 1. What is the purpose of this study?

There are a number of ways that a child's speech can be recorded and assessed. The purpose of this study is to develop the method used to record and assess speech in children with a cleft palate. This method will then be used in another project (the TOPS trial) which aims to find out the best age at which to repair a cleft palate in order to give the child the best possible speech.

#### 2. Why has my child been invited to take part?

The TOPS speech therapist at <Centre Name> is inviting all infants and children, aged between 10 and 14 months, 34 and 46 months and 58 and 70 months, to take part in this pilot study. Your child does not need to have a cleft palate for to take part.

#### 3. Does my child have to take part?

No, the research is voluntary. It is up to you to decide whether you take part. We will describe the study and go through this information sheet with you. You will also be given a copy of this information to take home. Should you decide that you would like your child to participate we will ask you to sign a consent form. You are free to withdraw your child from the study at any time, without giving a reason.

If you decide that you do not want your child to participate in this study the care they will receive will not be affected and will be the standard care provided at <Centre Name>.



&lt;Letter Headed Paper&gt;

Participant identifier Number									
-------------------------------	--	--	--	--	--	--	--	--	--

#### 4. What will happen if I choose for my child to take part?

##### *If your child is aged 14 months or younger*

Your speech therapist will make an audio and video recording of a play situation between you and your child. The purpose of this recording is to analyse the babbling of your child as it is known to be of importance for the language development.

##### *If your child is aged 34 months or older*

At the visit the speech therapist will ask your child to say a number of words (between 30 and 36) that have been carefully selected to allow assessment of all aspects of your child's speech. The speech therapist will make an audio and video recording of your child saying these words, and also a recording from spontaneous speech during a play session.

If your child is aged 58 months or older, your child will be asked to repeat sentences and retell a story. We will also ask your child to speak into a special microphone connected to a computer. This will assess how much nasal interference there is with your child's speech. You will also be asked to complete a very short questionnaire about how understandable your child's speech is to different people.

#### 5. What happens to the video recording?

The audio/video recording of your child will be used as part of the training of your speech therapist. It will also be used to develop a training package for all of the speech and language therapists involved in the TOPS trial.

We are doing this so that all of the speech therapists in the TOPS trial follow the same method. We would also like to ask your permission to use this recording to help train speech therapists involved in future studies.

#### 6. What will I have to do if my child takes part?

We would like you to keep the appointment made to see your child's speech therapist, in some cases this will be a usual visit or you may be asked to come for an additional appointment.

Your visit will last around 40-60 minutes.

#### 7. Are there any possible disadvantages and risks or side-effects of taking part?

The speech assessment made by the speech therapist is standard practice with no known risk to your child. The audio and video recording has no known risk to your child.

#### 8. What are the possible benefits of taking part?

Taking part in this study is unlikely to provide any direct benefit to your child. However, your child's recording will help to train speech and language therapists taking part in the TOPS trial which aims to find out if the timing of surgery for cleft palate repair influences a child's speech. The methods we develop for assessing speech may also help improve how we do future research and how speech is assessed in clinical practice.

#### 9. What will happen if something goes wrong?

In the event that something does go wrong due to negligence then you may have grounds for legal action for compensation against <Centre Name> but you may have to pay your legal costs.



&lt;Letter Headed Paper&gt;

Participant identifier Number									
-------------------------------	--	--	--	--	--	--	--	--	--

If you have a concern about any aspect of the pilot study you should ask to speak to a member of the cleft team who will do their best to answer your questions (contact number below).

The normal complaints mechanisms in place at <Centre Name> will still be available to you. Details can be obtained from the hospital.

#### 10. What happens if I want to withdraw my child from the study?

You may withdraw your child from the study at any time if you wish. If you withdraw your child from the study your child's ongoing and future care will not be affected by your decision. If you choose to withdraw your child from the study you may also choose for audio/video recordings already made to be destroyed.

#### 11. Will my child taking part in the study be kept confidential?

All information that is collected about you and your child during the course of the study will be kept strictly confidential, and any information that leaves <centre name> will have your child's name and address removed.

We would like to ask your permission to use the audio and video recording for the training of speech and language therapists involved in the TOPS trial and also in future studies about cleft palate. To do this, a copy will be sent to the Data Coordinating Centre in Liverpool who will store the audio and video recording securely and identified by a unique number only. We would also like to ask your permission for a copy of the consent form, which will have your and your child's name on it, to be sent to the Data Coordinating Centre at the University of Liverpool.

All legal requirements applying to research of this kind will be strictly adhered to.

#### 12. What will happen to the results of the study?

The results of the sample speech recordings made in this study will be used to standardise the method of speech sample collection across the TOPS trial. The TOPS trial will assess the effects of the timing of primary surgery for cleft palate on speech development. If you would like a copy of the final TOPS trial report you can indicate so on the consent form.

#### 13. Who is organising and funding the research?

This study and the TOPS trial have been planned by an international collaboration of cleft specialists. The Administrative Centre for the projects is the University of Manchester, UK, and the Data Coordinating Centre for the projects is the University of Liverpool, UK. The study is funded by the National Institute of Dental and Craniofacial Research in the USA.

#### 14. Who has reviewed the study?

All research is looked at by an independent group of people called a research ethics committee to protect you and your child's safety, rights, wellbeing, and dignity. This study has been reviewed and given a favourable opinion by Yorkshire and the Humber – Leeds East Research Ethics Committee.

#### Contact for further information

If you would like more information about the study please contact:

<Site Coordinator Name>

<Site coordinator Contact Number>

Participant Identifier

**Timing Of Primary Surgery For Cleft Palate (TOPS)-  
Pilot study to develop methods for speech and language assessment**

**CONSENT FORM FOR PARENTS**

Research Study Entitled: **Timing Of Primary Surgery For Cleft Palate (TOPS) Pilot study to develop methods for speech and language assessment.**

Centre Name: **<Centre Name/s>**

Name of Researchers: **<Names of all researches in involved centres>**

To be filled in by the parent/guardian  
Once you have read and understood each statement **please tick (✓) and initial**

**Agreement to take part in the study**

		Tick box (✓)	Initial
1.	I confirm that I have read and understand the information sheet (version number 3.0, dated, 01-May-2013) for the above study. I have had the opportunity to consider the information and ask questions and have had these answered satisfactorily.	<input type="checkbox"/>	
2.	I understand that the participation of my child is voluntary and that I and my child are free to withdraw at any time, without giving any reason, without our medical care or legal rights being affected.	<input type="checkbox"/>	
3.	I understand that data collected during the study may be looked at by individuals from the research team for training purposes, representatives of the sponsor, from regulatory authorities or from the organization delivering healthcare, where it is relevant to my child participating in this research. I give permission for these individuals to have access to my child's records.	<input type="checkbox"/>	
4.	I agree to copies of my consent form to be sent to the Data Coordinating Centre at the University of Liverpool	<input type="checkbox"/>	
5.	I agree for the recording to be sent to the University of Liverpool	<input type="checkbox"/>	
6.	I agree to audio and video recordings of my child being made and used to train speech and language therapists participating in the TOPS trial.	<input type="checkbox"/>	
7.	I agree to audio and video recording of my child being made and used to train speech and language therapists taking part in other cleft palate research.	<input type="checkbox"/>	
8.	I agree to take part in the above study and I also agree for my child to take part in the above study.	<input type="checkbox"/>	
9.	I would like/ would not like (delete as appropriate) a copy of the final report for the TOPS trial.	<input type="checkbox"/>	

\_\_\_\_\_  
Name of Child

\_\_\_\_\_  
Child's date of birth (dd-mm-yy)

\_\_\_\_\_  
Name of Parent/Guardian

\_\_\_\_\_  
Parent signature

\_\_\_\_\_  
Date signed (dd-mm-yyyy)

\_\_\_\_\_  
Name of Researcher

\_\_\_\_\_  
Signature of Researcher

\_\_\_\_\_  
Date signed (dd-mm-yyyy)

When completed, 2 copies need to be made, 1 for the participant, 1 for the investigator site file and the original must be kept in the medical notes. A copy of the consent form only should be faxed to the Data Coordinating Centre on +44 (0) 151 282 4721

Centre Name	
-------------	--

Centre ID	
-----------	--

## Important changes to the TOPS trial

Dear Parent,

The TOPS trial that you and your child are taking part in will assess the timing of primary surgery in children with cleft palate. We have made some changes since you agreed to be in the trial and would like to let you know about these and to check you are happy with them. There are two changes aimed at improving the data we collect about your child's speech:

1. We would like to send a questionnaire to other therapists outside of <centre name> who have provided speech therapy for your child. This questionnaire will ask how many and what type of speech therapy sessions your child has had.
2. When you attend for your child's age 5 speech follow up we will ask you to complete a short questionnaire about how well your child is understood by others. The questionnaire has 7 questions and takes about 5 minutes to complete.

These changes have been looked at and approved by an independent group of people called a research ethics committee (The Yorkshire and the Humber– Leeds East Research Ethics Committee).

Please tell us if you are happy with each of these changes, or not, by completing the section below and returning this form in the addressed envelope provided. We have included a copy of the information for you to keep.

If you would like more information about these changes before you make a decision please contact:

<Site Coordinator Name>, <Site coordinator Contact Number>

Please tick ✓ and initial in the spaces below

	Tick (✓)	Initials
I agree to my local speech therapist being contacted about my child's speech therapy sessions.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
I am happy with the changes made to the 5 year follow up visit and understand I will be asked to complete a short, 5 minute, questionnaire when I attend.	Yes <input type="checkbox"/> No <input type="checkbox"/>	

Your name	
-----------	--

Your signature		Today's Date	
----------------	--	--------------	--

Your child's name		Your child's date of birth	
-------------------	--	----------------------------	--

### To be completed by the research team

Randomisation Number								
----------------------	--	--	--	--	--	--	--	--

Date sent/given to parent	d	d	m	m	y	y	Sent by (Signature)	
---------------------------	---	---	---	---	---	---	---------------------	--

Date received at site	d	d	m	m	y	y	Received by (Signature)	
-----------------------	---	---	---	---	---	---	-------------------------	--

When complete, 2 copies need to be made, 1 for the participant, 1 for the investigator site file and the original must be kept in the medical notes. A copy of the consent form only should be faxed to the

## Supplementary Material No. 4: TOPS Trial Committees

### 1.1 Trial Management Group (TMG)

The Trial Management Group (TMG) comprises members of the Administrative and Data Coordinating Centres and representatives of the core speech group and National Institute of Dental and Craniofacial Research. The Trial Management Group is responsible for the day-to-day running and management of the trial. The Trial Management Group will meet monthly in the first instance and a minimum of four times a year, attendance at Trial Management Group meetings will be by teleconference. Other meetings will be held by teleconference call as needed. Telephone and email will be a primary means of daily communication between members of the Trial Management Group.

### 1.2 Trial Steering Committee (TSC)

The Trial Steering Committee will be composed of the trial investigators, members of the trial team at the Administrative and Data Coordinating Centres in addition to an independent chairperson and independent experts in the field of cleft palate surgery, speech therapy and biostatistics.

The role of the Trial Steering Committee is to provide overall supervision for the trial and provide advice through its independent Chairman. The ultimate decision for the continuation of the trial lies with the Trial Steering Committee. The Trial Steering Committee will meet at least annually by teleconference. Other meetings will be held by bimonthly teleconference call as needed. E-mail will be a primary means of communication between members of the Trial Steering Committee. The Trial Steering Committee may also make recommendations to the Funder who may withdraw funding of the study.

### 1.3 Data and Safety Monitoring Board (DSMB)

The composition of the Data and Safety Monitoring Board will be decided by the National Institute of Health / National Institute of Dental and Craniofacial Research (NIH/NIDCR) and the initial committee meeting will be convened prior to the trial commencing.

The Data and Safety Monitoring Board is an independent (should not be involved with the trial in any other way or have some competing interest that could impact on the trial) multidisciplinary group consisting of at least one statistician and at least one clinician that,

## Supplementary Material No 4.0 V1.0 05022019

collectively, have experience in the management of children with cleft palate and in the conduct of randomised controlled trials.

The Data and Safety Monitoring Board will be responsible for reviewing and assessing recruitment, interim monitoring of safety, trial conduct and external data.

The full terms of reference and roles of the Data and Safety Monitoring Board are detailed in the Data and Safety Monitoring Board Charter and a copy of the open minutes from each DSMB meeting will be provided to the Program Official at National Institute of Dental and Craniofacial Research.

For peer review only

Supplementary Material No 5.0 V2.0 15/05/2019

## Supplementary Material No. 5:

### Ethics Approval and Summary of substantial protocol amendments

#### Research Ethics Committees Approval

In the UK, the TOPS Protocol version 1.1 and accompanying consent forms and their amendments have been approved by the Multicentre Research Ethics Committee in the UK (Yorkshire and the Humber – Leeds East) on 008 January 2010.

In Brazil, approvals were gained from the Ethics in Research on Human Beings Commission (Comitê de Ética em Pesquisa em Seres Humanos) of the Hospital for Rehabilitation of Craniofacial Anomalies (Hospital de Reabilitação de Anomalias Craniofaciais Universidade da São Paulo, HRAC-USP), and from the National Ethics in Research Commission (Comissão Nacional de Ética em Pesquisa, CONEP from the Conselho Nacional de Saúde).

In Denmark, approvals were received from the Institutional Review Board for the Central Denmark Region (De Videnskabsetiske Komiteer For Region Midtjylland).

In Sweden, the ethics committee approving the TOPS Protocol was the Regional Ethical Review Board in Stockholm (Regionala Etikprövningsnämnden i Stockholm)

In Norway, the regional committee for medical and health care research ethics in South-east Norway (Regional komité for medisinsk forskningsetikk sør-øst Norge, REK sør-øst B) gave ethical approval for the TOPS project. Table 1 summarises the international approval for the TOPS protocol and subsequent amendments.

Table 1: International approval of the TOPS protocol and subsequent amendments by the national and local Research Ethics Committees

Protocol		Approval Dates				
Version No	Version Date	UK	Sweden	Denmark	Norway	Brazil
1.1	02/11/2009	08/01/2010				
2	10/03/2010	26/05/2010				
2.1	06/09/2010	28/09/2010	18/11/2010	04/07/2011	20/09/2011	11/03/2011, 27/04/2011, 10/05/2011 *
3	01/05/2013	27/06/2013	11/02/2014	09/05/2014	18/12/2013	26/08/2014
4	26/08/2015	01/10/2015	22/12/2015	09/11/2016	12/08/2016	06/11/2016
5	22/08/2018	16/11/2018	03/01/2019	21/03/2019	TBC	30/04/2019

\* Local REC approval followed by the national REC approval in Brazil

TBC: to be confirmed



Supplementary Material No 5.0 V2.0 15/05/2019

### **TOPS Protocol Version 2.0 (10 Mar 2010)**

There were major amendments from version 1.0 to version 2.0, as summarised below.

The secondary outcomes of the trial have been amended to include growth at age 12 months, which will be assessed by heel to crown length, nude weight and occipitofrontal circumference.

In addition, total speech and language intervention together with total speech therapy will be assessed at age 3 and age 5 years.

The wording of the postoperative complications outcome has been amended to “Postoperative/long term complications: infection, wound dehiscence and fistula”.

The TOPS protocol has been amended to include a pilot speech study, which will allow the training of speech therapists, involved in the TOPS trial, in the collection of a speech sample. The amendment requests that sample speech recordings are made in children with a cleft palate. Between 1 and 5 recordings will be made for each of the three age groups: 10-12 months, 34-38 months, 58-62 months. The number of recordings made will depend upon the experience of the speech therapists. A set of additional parent information sheets and consent forms have been included for parents and children who would like to participate in this pilot study.

### **TOPS Protocol Version 3.0 (01 May 2013)**

There were major amendments to V3.0. Key changes are summarised below:

The timing of adverse event reporting was clarified so that adverse events taking place in the 30 day post-operative period only were reported. Unanticipated problems will continue to be reported throughout the full trial duration.

Changes were made into the audiology assessments. After discussion with the OM8-30 questionnaire, developer concerns were raised about the version control and validation of the questionnaire. The OM8-30 questionnaire for the assessment for glue ear will no longer be used.

The inclusion/exclusion criteria was amended. Participants may now be included in the trial if they have Van Der Woude syndrome, as this syndrome is not considered to have an impact on development or speech and language. The exclusion criteria now states:

Infants with syndromic cleft palate (except Van der Woude syndrome, which can be included if hearing is not affected) or severe developmental delay.

Initially it was planned for teams to make follow up phone calls with participants at age 2 and 4 years. However, patients are regularly seen in clinic and so this was no longer considered necessary.

Supplementary Material No 5.0 V2.0 15/05/2019

To help reduce the burden to sites data entry will now be completed centrally at the Data Coordinating Centre and this has been clarified in the protocol.

Other changes included amendments to the parent information sheets and consent forms (PISC) format to help ensure that the correct version (pilot study or main trial) was used. The PISC was also amended to reflect the changes to assessments and follow up telephone calls and to include an optional item for parents to consent to be contacted by other researchers regarding related research.

**TOPS Protocol Version 4.0 (26 Aug 2015)** The key changes introduced with major amendments from V3.0 to V4.0 were a very short questionnaire for the participants' parents (ICS (Intelligibility in context scale) questionnaire) and a new supplementary Parent Information and Consent form to arrange for consent to collect information using the ICS questionnaire. Furthermore, changes were made to the Pilot Parent Information and Consent form and there were also modifications to the secondary outcome measures. Finally, changes were made to the section of the protocol covering indemnity. Please see a brief summary of the changes listed below:

1. Intelligibility in context scale (ICS) questionnaire added to the speech assessments at 5 years
2. New supplementary Parent Information and Consent form, asking for consent to collect data using ICS and from local speech therapists
3. Pilot Parent Information and Consent form was amended, it now also covers collection of data using ICS and nasometer at 5 years, and includes an additional consent clause #5, stating that recordings will be sent to the Data Coordinating Centre in Liverpool.
4. Changes to secondary outcomes summarised:
  - i. Change of secondary outcome "Velopharyngeal composite score summary at age 3 years and 5 years", to "Velopharyngeal composite score summary at 5 years", as VPC-sum at 3 years is no longer possible (because this measure was recently found not to be reliable with 3year olds).
  - ii. Addition of detail to definition of secondary outcome measures No. 38: the details added now show the components of the outcome measures; The provision of detail made it necessary to split the outcome measure "Articulation" into two outcome measures: "Articulation at age 3 years" and "Articulation at age 5 years", as these are assessed in different ways; Also, the outcome measure "Audiological assessment (audiometry and tympanometry)" has now been split into "Hearing level" and "Middle ear function". While this addition of detail results in an increase of the number of secondary outcome measures listed, the actual outcome measures No. 3-8 have not changed since the last version of the protocol;
  - iii. Removal of the two secondary outcome measures "Total speech and language therapist intervention at age 3 and age 5 years" and "Total speech therapy sessions at age 3 and age 5 years" as these are recorded as background data, and do no longer constitute secondary outcome measures.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17
5. Section 14, Indemnity (page 77 in protocol): Section had initially described University of Manchester as a “cosponsor for international sites” – this has been corrected and clarified in detail: the University of Manchester is the sole Sponsor for the TOPS trial. For sites in the United Kingdom, the University of Manchester as Sponsor will provide Indemnity for the trial protocol. For all other trial sites, the University of Manchester will ensure that appropriate indemnity is in place at the trial site via the contractual agreements in place. The roles and responsibilities of the Administrative Centre, Data Coordinating Centre and the trial sites involved in the TOPS trial will be defined in a Division of Responsibilities document, which will form part of any signed contractual agreements.

### 18 **TOPS Protocol Version 5.0 (22 August 2018)**

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

The key change in this substantial amendment was introduction of additional outcome measures to enable the trial team to make the best use of the existing data collected. The amendment included the addition of nasalance score to the TOPS Statistical Analysis Plan, as an exploratory analysis but not as a standalone outcome. This is to compare consistency between Speech and Language Therapist’s assessment of hypernasality and nasalance score. The additional outcome measures added to the protocol version 5.0 are summarised below along with the rationale for the changes:

- 31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47
1. VPC-rate was added because it is important to assess velopharyngeal function not only on single words but also on spontaneous speech at age 5, the most common communication condition; this is the same outcome measure as for the 3 year follow up assessment.
  2. Velopharyngeal insufficiency symptoms from single words will support the overall assessment of velopharyngeal function assessed from spontaneous speech at age 3.
  3. Assessment of oral consonant errors contributes to a better understanding of the speech errors made by children with Cleft Palate; this is the same outcome measure as for the 5 year assessment. This change will make it possible to follow the prevalence longitudinally.

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The above changes to the outcome measures will not affect site activity nor require any additional data to be collected from patients or affect their safety.

# Timing Of Primary Surgery for cleft palate (TOPS): Protocol for a randomised trial of palate surgery at 6 months versus 12 months of age

## Reporting checklist for protocol of a clinical trial

	Reporting Item	Page Number
Title	<a href="#">#1</a> Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a> Trial identifier and registry name. If not yet registered, name of intended registry	1
Trial registration: data set	<a href="#">#2b</a> All items from the World Health Organization Trial Registration Data Set	12
Protocol version	<a href="#">#3</a> Date and version identifier	1 & Supplementary files
Funding	<a href="#">#4</a> Sources and types of financial, material, and other support	1 and 13
Roles and responsibilities: contributorship	<a href="#">#5a</a> Names, affiliations, and roles of protocol contributors	12-13
Roles and responsibilities: sponsor contact information	<a href="#">#5b</a> Name and contact information for the trial sponsor	13
Roles and responsibilities: sponsor and funder	<a href="#">#5c</a> Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they	13 and Supplementary material No 4

will have ultimate authority over any of these activities

1			
2			
3			
4	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the
5	responsibilities:		coordinating centre, steering committee,
6	committees		endpoint adjudication committee, data
7			management team, and other individuals or
8			groups overseeing the trial, if applicable (see
9			Item 21a for data monitoring committee)
10			
11			
12			
13			
14	Background and	<a href="#">#6a</a>	Description of research question and
15	rationale		justification for undertaking the trial, including
16			summary of relevant studies (published and
17			unpublished) examining benefits and harms for
18			each intervention
19			
20			
21			
22	Background and	<a href="#">#6b</a>	Explanation for choice of comparators
23	rationale: choice of		
24	comparators		
25			
26			
27	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses
28			
29			
30	Trial design	<a href="#">#8</a>	Description of trial design including type of trial
31			(eg, parallel group, crossover, factorial, single
32			group), allocation ratio, and framework (eg,
33			superiority, equivalence, non-inferiority,
34			exploratory)
35			
36			
37			
38	Study setting	<a href="#">#9</a>	Description of study settings (eg, community
39			clinic, academic hospital) and list of countries
40			where data will be collected. Reference to
41			where list of study sites can be obtained
42			
43			
44			
45	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants.
46			If applicable, eligibility criteria for study centres
47			and individuals who will perform the
48			interventions (eg, surgeons, psychotherapists)
49			
50			
51			
52	Interventions:	<a href="#">#11a</a>	Interventions for each group with sufficient
53	description		detail to allow replication, including how and
54			when they will be administered
55			
56			
57			
58			
59			
60			

1 2 3 4 5 6 7 8	Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	NA
9 10 11 12 13 14 15	Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	4, 7 and 8
16 17 18 19	Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
20 21 22 23 24 25 26 27 28 29 30 31 32 33	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	5-7
34 35 36 37 38 39 40 41	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8-9 & Figure 1
42 43 44 45 46 47 48 49	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
50 51 52 53 54 55 56 57 58	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	3&10

1	Allocation:	<a href="#">#16a</a>	Method of generating the allocation sequence	4
2	sequence		(eg, computer-generated random numbers),	
3	generation		and list of any factors for stratification. To	
4			reduce predictability of a random sequence,	
5			details of any planned restriction (eg, blocking)	
6			should be provided in a separate document	
7			that is unavailable to those who enrol	
8			participants or assign interventions	
9				
10				
11				
12				
13	Allocation	<a href="#">#16b</a>	Mechanism of implementing the allocation	NA
14	concealment		sequence (eg, central telephone; sequentially	
15	mechanism		numbered, opaque, sealed envelopes),	
16			describing any steps to conceal the sequence	
17			until interventions are assigned	
18				
19				
20				
21				
22	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence,	4-5
23	implementation		who will enrol participants, and who will assign	
24			participants to interventions	
25				
26				
27	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to	5
28			interventions (eg, trial participants, care	
29			providers, outcome assessors, data analysts),	
30			and how	
31				
32				
33				
34	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which	NA/ speech
35	emergency		unblinding is permissible, and procedure for	assessments are
36	unblinding		revealing a participant's allocated intervention	carried out under
37			during the trial	blinded conditions
38				
39				
40				
41	Data collection	<a href="#">#18a</a>	Plans for assessment and collection of	9-10
42	plan		outcome, baseline, and other trial data,	
43			including any related processes to promote	
44			data quality (eg, duplicate measurements,	
45			training of assessors) and a description of	
46			study instruments (eg, questionnaires,	
47			laboratory tests) along with their reliability and	
48			validity, if known. Reference to where data	
49			collection forms can be found, if not in the	
50			protocol	
51				
52				
53				
54				
55				
56				
57				
58				

1	Data collection	<a href="#">#18b</a>	Plans to promote participant retention and	10 and Text box 1
2	plan: retention		complete follow-up, including list of any	
3			outcome data to be collected for participants	
4			who discontinue or deviate from intervention	
5			protocols	
6				
7				
8				
9	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and	10
10			storage, including any related processes to	
11			promote data quality (eg, double data entry;	
12			range checks for data values). Reference to	
13			where details of data management procedures	
14			can be found, if not in the protocol	
15				
16				
17				
18				
19	Statistics:	<a href="#">#20a</a>	Statistical methods for analysing primary and	11
20	outcomes		secondary outcomes. Reference to where	
21			other details of the statistical analysis plan can	
22			be found, if not in the protocol	
23				
24				
25				
26	Statistics:	<a href="#">#20b</a>	Methods for any additional analyses (eg,	11 and 12
27	additional analyses		subgroup and adjusted analyses)	
28				
29				
30	Statistics: analysis	<a href="#">#20c</a>	Definition of analysis population relating to	11 and 12
31	population and		protocol non-adherence (eg, as randomised	
32	missing data		analysis), and any statistical methods to	
33			handle missing data (eg, multiple imputation)	
34				
35				
36	Data monitoring:	<a href="#">#21a</a>	Composition of data monitoring committee	12 and
37	formal committee		(DMC); summary of its role and reporting	Supplementary
38			structure; statement of whether it is	material No 1
39			independent from the sponsor and competing	
40			interests; and reference to where further	
41			details about its charter can be found, if not in	
42			the protocol. Alternatively, an explanation of	
43			why a DMC is not needed	
44				
45				
46				
47				
48				
49	Data monitoring:	<a href="#">#21b</a>	Description of any interim analyses and	12 and
50	interim analysis		stopping guidelines, including who will have	Supplementary
51			access to these interim results and make the	Material No 1
52			final decision to terminate the trial	
53				
54				
55				
56				
57				
58				



1	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	8, 12 and Supplementary Material No 1
2				
3				
4				
5				
6				
7				
8	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	11 and Supplementary Material No 4
9				
10				
11				
12				
13				
14	Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	1, 1 and Supplementary Material No 5
15				
16				
17				
18				
19				
20	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	Supplementary Material No 5
21				
22				
23				
24				
25				
26				
27				
28	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4 and supplementary Materials No 1, 2 and 3
29				
30				
31				
32				
33	Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	Supplementary Materials 2 and 3
34				
35				
36				
37				
38				
39	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12 & Supplementary Materials No 1 and 2
40				
41				
42				
43				
44				
45	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	13
46				
47				
48				
49				
50				
51	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	12-13
52				
53				
54				
55				
56				
57				
58				

1	Ancillary and post	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial	NA
2	trial care		care, and for compensation to those who	
3			suffer harm from trial participation	
4				
5				
6	Dissemination	<a href="#">#31a</a>	Plans for investigators and sponsor to	12
7	policy: trial results		communicate trial results to participants,	
8			healthcare professionals, the public, and other	
9			relevant groups (eg, via publication, reporting	
10			in results databases, or other data sharing	
11			arrangements), including any publication	
12			restrictions	
13				
14				
15				
16				
17	Dissemination	<a href="#">#31b</a>	Authorship eligibility guidelines and any	12
18	policy: authorship		intended use of professional writers	
19				
20				
21	Dissemination	<a href="#">#31c</a>	Plans, if any, for granting public access to the	12
22	policy: reproducible		full protocol, participant-level dataset, and	
23	research		statistical code	
24				
25				
26				
27	Informed consent	<a href="#">#32</a>	Model consent form and other related	Supplementary
28	materials		documentation given to participants and	Materials No 1, 2 and
29			authorised surrogates	3
30				
31				
32	Biological	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and	4, 10 and
33	specimens		storage of biological specimens for genetic or	Supplementary
34			molecular analysis in the current trial and for	materials No 1
35			future use in ancillary studies, if applicable	
36				
37				
38				

39 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-  
 40 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made  
 41 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58